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US pharmaceutical company leaders who lack strategies for developing and 
implementing open innovation (OI) Research & Development (R&D) projects may 
experience weakened competitive positioning in the industry. Grounded in the open 
innovation capability framework, the purpose of this qualitative single case study was to 
explore implementation strategies R&D directors use to implement OI R&D projects in 
the US. Participants were five US pharmaceutical R&D directors from a single 
organization. Data were collected using semistructured interviews, public information, 
and OI literature and analyzed using Castleberry and Nolen’s five-step model. Four 
themes emerged: roles and responsibilities, business and OI strategy alignment, 
leadership attention, and OI decision-making. A key recommendation for pharmaceutical 
R&D directors is to develop a clear OI strategy aligned with the business strategy and 
assemble two teams, a search and evaluation team and an alliance management team, to 
help identify and assimilate OI projects. Positive social change implications include the 
potential for pharmaceutical leaders using more efficient methods of R&D, resulting in 
the discovery and development of novel therapeutics at a lower cost to patients, making it 
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Section 1: Foundation of the Study 
Background of the Problem 
The US pharmaceutical industry supports over 3.4 million jobs across the US in  
multiple industries and added an estimated $800 billion to the economy in 2015 
(Muratoglu, 2017). It is a major contributor to the US economy and considered a 
significant part of the global market (Lakdawalla, 2018). Downs & Velamuri (2016) said 
over the last 60 years, inflation-adjusted research and development (R&D) expenditure 
per molecule brought to market increased significantly. Despite billions of dollars the US 
pharmaceutical industry collectively spends on R&D annually, the rate of novel therapy 
output is declining versus historical productivity levels (Schumacher et al., 2016). 
Problem Statement 
US pharmaceutical company leaders experience challenges in terms of bringing 
novel therapeutic agents through the R&D process to generate a sufficient return on 
investment (ROI; DiMasi et al., 2020). OI strategies may increase the net present value of 
projects by 70% compared to closed innovation projects (Chesbrough, 2017; Hosseini et 
al., 2017). The general business problem is that US pharmaceutical company leaders’ 
failure to implement an OI business model may lead to less innovative and competitive 
companies. The specific business problem is that some US pharmaceutical company 
leaders lack strategies for developing and implementing OI R&D projects.  
Purpose Statement 
The purpose of this qualitative single case study was to explore strategies US 




projects. The targeted population comprised five US pharmaceutical R&D directors in 
one pharmaceutical firm that successfully used OI strategies to develop and implement 
R&D drug development projects. The US pharmaceutical company is in the northeastern 
region of the United States. My research findings may enhance US pharmaceutical 
leaders’ capacities to increase ROI, decrease operational costs, and positively benefit 
local communities through increased tax revenues and employment opportunities. 
Furthermore, the efficient discovery and production of novel therapies may lead to a 
better quality of life for many patients. 
Nature of the Study 
I used a qualitative single case study design to explore strategies five US 
pharmaceutical company leaders used for developing and implementing successful OI 
pharmaceutical R&D projects. Yin (2018) said a qualitative case study method can be 
used for researching a contemporary topic and providing a detailed description of the unit 
of analysis. A quantitative methodology was not appropriate for this exploratory study. It 
is used to measure and analyze variables’ characteristics and relationships through 
statistical analysis (Pessoa et al., 2019). Marshall and Rossman (2016) said the mixed 
methods approach entails collecting both qualitative and quantitative data. I did not use a 
mixed methods approach because the quantitative method was not necessary for 
addressing the purpose of my study.  
Soleimani et al. (2018) said researchers can use the case study design to 
understand the nature and complexity of processes taking place in the context of a 




Tisdell, 2016). The ethnography design was not appropriate for my research because I 
was not studying culture or social groups. James (2018) said narrative inquiry consists of 
in-depth interviews to collect, analyze, and interpret peoples’ life stories. The narrative 
inquiry was not a suitable design because the intent of my study was not to provide a 
summary of personal accounts of participants’ life stories related to events. The 
phenomenology design was not appropriate because I was not researching the 
fundamental nature of the meanings of human experiences with phenomena. 
Phenomenologists are interested in people’s conscious experience of their everyday life 
and social action (Smith, 2018). Therefore, a single-case design was the most appropriate 
design to identify and explore strategies managers used to develop and implement OI 
pharmaceutical R&D projects. 
Research Question 
What are the strategies that US pharmaceutical company leaders used to develop 
and implement OI R&D projects? 
Interview Questions 
1. What strategies did you use to implement an OI business model for R&D 
projects? 
2. How did you identify new R&D projects to pursue using an OI strategy? 
3. How did you decide which OI strategy to use for an OI R&D project? 





5. What organizational capabilities did you consider when pursuing a given OI 
R&D project? 
6. How did you decide which capabilities are important to implement an OI 
R&D project? 
7. How did you decide which employees should participate in the 
implementation of OI R&D projects? 
8. If your organizational culture supports OI R&D, describe how your culture 
supports the implementation of OI R&D projects. 
9. If the organizational culture supports OI, describe the strategies used to align 
the organizational structure to support OI R&D projects. 
10. What else can you tell me you did to enhance OI strategies? 
Theoretical or Conceptual Framework 
Since the inception of the OI theory, many researchers have studied the 
phenomenon. Hosseini et al. (2017) developed an OI capability framework (OICF), 
which is intended to serve as a foundation for assessing OI competencies of individuals in 
an organization. Leaders could use the OICF as a guide for implementing OI in their 
organization. 
Hosseini et al. (2017) identified capabilities with similar characteristics and 
qualities and grouped these capabilities into six factors: strategic alignment, governance, 
methods, IT, people, and culture. The OICF is comprised of 23 capability areas stratified 
among these six factors. The six factors identified are capabilities relevant to 




relevance, and for understanding the strategies the participating pharmaceutical 
organizations’ leaders used to select and implement OI R&D projects. I therefore 
expected the OICF framework to be useful for understanding strategies organizational 
leaders used to develop and implement OI in the context of the pharmaceutical industry. 
Operational Definitions 
Open innovation (OI): A distributed innovation process based on purposively 
managed knowledge flows across organizational boundaries. OI provides insights into 
how firms can harness inflows and outflows of knowledge to improve their innovation 
success (Bogers et al., 2018). 
Assumptions, Limitations, and Delimitations 
In this subsection, I discuss the various assumptions, limitations, and 
delimitations of my research. Investigators should plan the research process for the study. 
Furthermore, assumptions, limitations, and delimitations of the study should be outlined. 
Assumptions 
Assumptions are facts the researcher assumes to be true (Marshall & Rossman, 
2016). I made four assumptions in this study. My first assumption was that 
pharmaceutical R&D directors provided adequate and truthful responses during 
interviews. My second assumption was that pharmaceutical R&D directors shared 
valuable rich information regarding their OI implementation strategies and experience. 
My third assumption was that the OICF applied to the context of the pharmaceutical 




directors experienced with implementing OI drug development projects was enough to 
provide rich content for a single case study. 
Limitations 
One of the limitations of my study involved the choice of a single case study of 
one pharmaceutical company located in the northeastern region of the US, which may not 
represent all information possible from companies. Yin (2018) suggested single case 
studies are exposed to limitations because there are more analytic benefits from having 
multiple cases. Furthermore, the study findings may not apply to all US pharmaceutical 
companies because of the limited geographical scope of the study.  
Another limitation of my study was the participant sample size, because I 
interviewed only five pharmaceutical R&D directors. The final limitation of my study 
involves the use of semistructured interviews as my primary data collection method. 
Bloomberg and Volpe (2019) suggested that not all interviewees are equally cooperative, 
articulate, and perceptive. Many studies have limitations, so the investigators need to be 
transparent regarding the limitations of their findings 
Delimitations 
Delimitations are limits imposed by the researchers’ study design and the 
intentional choices the researcher makes to investigate the research problem (Bloomberg 
& Volpe, 2019). The first delimitation of my study will be that the study participants are 
from one pharmaceutical company in the northeastern region of the US A second 
delimitation will be that the participants are pharmaceutical R&D directors with 




number of interviewees used to collect the data. Researchers should communicate the 
boundaries of their research study by stating their exclusionary and inclusionary 
decisions. 
Significance of the Study 
My study findings could be significant for leaders in pharmaceutical firms 
seeking to use OI strategies to improve their firms’ competitive positions in the market. 
Pharmaceutical leaders intending to implement an OI business model might be able to 
use implementation strategies that I discovered through my research. Pharmaceutical 
leaders may use the prospective framework to lead a more efficient and effective drug 
development process for reducing the cost of developing drugs and increasing 
pharmaceuticals firms’ efficacy. 
Contribution to Business Practice 
As pharmaceutical industry leaders struggle with controlling rising costs of drug 
development, they search for more efficient strategies and methods for discovering and 
developing novel therapeutics (Downs & Velamuri, 2016). Shaw (2017) said 
pharmaceutical leaders are leveraging OI business models to improve their biomedical 
innovation processes. However, proponents of OI typically encounter several barriers and 
challenges; leaders of pharmaceutical firms need to develop strategies to implement OI. 
If leaders of pharmaceutical firms had implementation frameworks for the OI business 
model, pharmaceutical leaders could improve their chances of being successful. If my 
research supports OICF relevance, pharmaceutical leaders may garner additional insights 




Implications for Social Change 
If my research findings are significant, pharmaceutical leaders implementing OI 
may increase the efficiency of discovering and developing novel therapeutics. An 
increase in the efficiency of discovering and developing novel therapeutics may lead to 
cost-effective therapeutic remedies that provide a better quality of life for many patients, 
and in some cases may save lives (Hunter et al., 2018). In addition, if the research bears 
favorable results, pharmaceutical leaders who implement proposed strategies may 
increase the viability of their organizations, which then may lead to employment 
opportunities for members of local communities and better life quality for communities. 
A Review of the Professional and Academic Literature 
The purpose of this qualitative exploratory single case study is to explore 
strategies that are critical to implementing an OI business model for pharmaceutical R&D 
projects. I examine literature in this review related to OI in general as well as in relation 
to the pharmaceutical industry and conceptual frameworks used to implement OI 
strategies. My intention was to discover recent scholarly literature regarding specific 
strategies for implementing OI in the pharmaceutical industry at the project level. I begin 
the literature review with an overview of OI, followed by OI and the pharmaceutical 
industry and a review of conceptual frameworks used to implement OI. 
 To construct the literature review, I obtained information through searches and 
reviews of recent research regarding OI. I also accessed peer-reviewed literature by using 
databases from the Walden University Library. The databases used to search for peer-




ABI/INFORM Complete. The search included keywords open innovation, open 
innovation AND pharmaceutical industry, open innovation AND implementation, open 
innovation AND strategy, and open innovation AND projects. To construct the literature 
review, I obtained information through searches and review of recent research around OI 
and selected articles that were relevant to my area of study. 
I searched the literature for peer-reviewed, full-text articles from 2016-2021. To 
maintain relevancy and satisfy university requirements, I selected a minimum of 85% of 
literature review sources published within 5 years of this study’s completion date. From 
the search results of peer-reviewed articles, I analyzed 83 articles relevant to my area of 
study and the conceptual framework for the review of the literature. Of the 83 articles, 6  
(7%) were published before 2016.  
Open Innovation 
OI is a business strategy that Chesbrough proposed in 2003. Chesbrough (2017) 
described the use of purposive inflows and outflows of knowledge to accelerate internal 
innovation and reduce the cost of R&D. Zhao et al. (2016) said the process of innovation 
has relied on external participants for many years and that enterprises always rely on both 
inflow and outflow of ideas, resources, and individuals. Furthermore, Conrado, et al., 
(2017) asserted that sharing of resources across organizations to support OI is an old idea. 
Conrado et al. posited that the scientific community is sharing more readily in recent 
years. External search for information and its integration in the context of OI is one 




Leaders can no longer rely only on internal resources to innovate. Zhao et al. 
(2016) said with economic globalization, managers of businesses can no longer rely 
solely on internal innovation to be successful. Leaders must develop resourceful methods 
to develop innovative products. Consequently, many leaders are focused on 
implementing OI to improve their product lines and sustain their competitive advantage. 
Cammarano et al. (2019) advocated that leaders adopt OI strategies to pursue exploration 
and diversification that may lead to radical innovation.  
Leaders that properly implement OI increase the innovation performance of firms. 
OI consists of many different practices and is not a dichotomous phenomenon. The main 
tenets of OI are collaborations with external partners, exploration of knowledge and 
technology, and exploitation of internal resources (Uribe-Echeberria et al., 2019).  
There are currently three recognized forms of OI. Managers engaged in bringing 
technologies into the firm are involved in inbound OI (Barchi& Greco, 2018; Marcolin et 
al., 2017; Shin et al., 2018). Inbound OI is a strategy managers' use to enhance 
employees’ knowledge necessary for meaningful innovations. Conversely, managers 
selling or licensing their internal innovations to other companies are engaged in outbound 
OI activities (Barchi& Greco, 2018; Marcolin et al., 2017; Shin et al., 2018). Leaders 
engaging in outbound OI sell unused innovations and technologies to obtain a pecuniary 
benefit. Collaborating, cooperating, and joint ventures to develop innovations are referred 
to as coupled OI because the innovation and exploitation process involves joint ventures 
(Marcolin et al., 2017; Shin et al., 2018). Regardless of the OI practice, the objective is to 




Despite the potential benefits of OI, firm leaders have encountered difficulties of 
successfully implementing OI. Cui et al. (2015) noted a survey of 107 European firms 
showed that 48% of managers were concerned with the difficulty of incorporating 
external knowledge into their innovation process. Incorporating external knowledge and 
technologies into organizations is one of the central tenets of OI. Cui et al. (2015) said 
significant internal supporting resources are vital to unlocking OI’s potential to contribute 
to innovation performance.  
Absorptive capacity is critical for managers assimilating external knowledge and 
technologies into a company (Milutinović et al., 2017). Absorptive capacity is the 
leader’s ability to recognize the value of new information, then integrate the information 
and apply it to marketable products (Fisher & Qualls, 2018; Greco et al., 2016; Xia & 
Roper, 2016; Xie et al., 2018). Greco et al. (2019) said OI strategies may improve 
innovation by shortening the innovator’s learning curve and fostering organizational 
learning. Decreasing the innovators’ learning curve can lead to value capture more 
swiftly. 
Milutinović et al. (2017) suggested IT-based tools can facilitate access to a large 
variety of ideas and accelerate the development of innovative new products and services. 
The joining of the OI paradigm and IT results in platforms for managers to facilitate 
easier access for customers and other potential participants willing to independently 
contribute to solving the specific problems of the company. 
The success of a business depends as much on the business model design and 




assets and equipment (Teece, 2018). Organizational leaders can use a business model as a 
guide to provide a pathway by which technological innovation and knowledge combined 
with the use of tangible and intangible assets are transformed into profits. 
OI Implementation 
To implement OI, organizational capabilities may need a higher level of 
development than closed innovation. Von Briel and Recker (2017) said the 
implementation of OI is not a straightforward process. Von Briel and Recker argued that 
even in an organization comfortable with embracing innovation a failed OI project 
implementation is possible. It is important to consider several potential barriers before 
engaging in OI such as the industry context, legal environment, supportive processes, 
innovation maturity, commitment, and the participants (Von Briel& Recker, 2017).  
Hosseini et al. (2017) said OI implementation needs a different employee mentality 
in comparison to a closed innovation environment. Hosseini et al. identified six high-level 
capabilities that are needed to implement OI strategies: strategic alignment, governance, 
methods, IT, people, and culture. Hosseini et al. proposed OICF expounded on the inbound 
OI and the coupled OI forms but Hosseini et al. proposed OICF did not address the 
capabilities needed for outbound OI. Outbound OI is less common than the other two 
categories of OI. 
 The foundational theory that OICF draws from is related to capability 
development. Proponents of the resource-based view (RBV) consider capabilities and 
assets as resources. With the RBV, assets can be tangible or intangible that organizational 




Hosseini et al., 2017). Managers have resources that can help them to achieve a 
competitive advantage (Barney, 1991; Barney et al., 2011; Hosseini et al., 2017). 
Managers can sustain competitive advantage if their product or service has four 
attributes: value, rareness, imitability, and non-substitutable (Barney, 1991; Barney et al., 
2011). An organization's employees have capabilities that are considered resources and if 
developed can provide a competitive advantage.  
Proponents of the dynamic capability theory (DCT) extend the RBV and 
differentiate between operational and dynamic capabilities. The concept of dynamic 
capabilities arises from a key limitation of the RBV of the firm. Dynamic resources help 
leaders of firms adjust their employee’s capability mix to adapt and keep the firm’s 
competitive advantage (Smart et al., 2007; Teece, 2018).  
Firms will inevitably not be strong in all aspects. A manager of a firm might excel 
at discovering new opportunities but be weak in terms of identifying new business 
models to exploit them. Leaders can use an OI business model to achieve competitive 
advantages providing they implement OI properly. Strategic alignment, governance, 
methods, IT, people, and culture can potentially provide a framework to guide managers 
in the pharmaceutical industry to implement OI successfully. 
Strategic alignment. 
Leaders in organizations must be able to adapt their OI processes in response to 
changes in their corporate environment. Leaders of firms need to make strategic decisions 
for OI to be successful. One such decision leaders need to make is how many channels 




consider levels of engagement in terms of these different collaborations. To garner 
benefits from OI, organizational leaders must align OI strategies with business strategies 
and engage with external partners.  
A proper degree of engagement with external partners that aligns with 
corresponding internal resources and processes is essential for improving the 
organization’s innovation performance with OI strategies (Dahlander et al., 2016). 
Leaders implementing OI need to provide systems and resources to discover 
opportunities and absorb ideas into their companies. Cui et al. (2015)said IT strategy 
alignment is directly linked to the success of the OI strategy. The alignment between IT 
strategies and the extent to which a leader uses OI strategies is critical for innovation 
success.  
IT is a vital component for leaders searching for OI projects. A proper degree of 
openness that goes along with corresponding internal resources and processes is essential 
for improving organizations’ innovation performance with OI strategies. Leaders of firms 
implementing OI need to provide mechanisms and resources to discover innovative 
opportunities and absorb them into the company.  
Cui et al. (2015) analyzed data from 225 firms engaged in OI in China and 
concluded that the alignment between IT flexibility and breadth enhances innovation and 
innovation volume, while the alignment between IT integration and depth positively 
affects innovation volume only. Cui et al. suggested firms need IT to transfer both 




helped leaders to transfer knowledge into and out of companies, easing the pathway to 
implementing OI.  
For a firm to benefit from OI, there is an initial investment in resources needed to 
increase the firm’s absorptive capacity. Absorptive capacity is the ability of an 
organizational leader to manage new knowledge and integrate new information into the 
organization and across departments (Xia & Roper, 2016; Xie et al., 2018). Rafique et al. 
(2018) argued that absorptive capacity is a function of infrastructure as well as the 
employees of the organization.  
Furthermore, Brunswicker and Chesbrough (2018) reported that in their most 
recent survey compared to their 2014 findings, 2.5 % of respondents abandoned the OI 
strategy for several reasons. Brunswicker and Chesbrough (2018) reported the 
respondents that abandoned the OI strategy frequently chose a “lack of required 
organizational structure,” followed by “no perceived benefits,” “too risky for assets and 
IP,” “too difficult to manage,” “lack of management capabilities,” and “too expensive. 
These results led to Brunswicker and Chesbrough (2018) to conclude that difficulties 
organizing for OI and implementing OI, may have led to manager’s frustration resulting 
in the abandonment of the OI strategy. Manager's frustration and difficulties with 
organizing for OI are other reasons supporting the need for an OICF.  
Leaders who can establish the availability of several external channels for 
gathering knowledge may grant access to innovation capabilities that a firm does not hold 
(Fu et al., 2018). The innovations that leaders discover using these external channels may 




successfully integrate these innovations into the business. Moreover, the firm’s managers 
may need to decide which channels provide the largest return on investment as the 
manager decides which channels to implement. R&D managers may find existing ideas 
or technologies outside their organizational boundaries and integrate the ideas and 
technologies to start or enhance internal R&D activities provided they have the available 
absorptive capacity.  
While implementing OI strategies, managers of firms need to be aware of the U-
shaped relationship (curvilinear) between adopting external technologies and a firm’s 
innovation performance. Although OI may help bolster a company’s innovative 
performance, if managers start too many projects at one time OI may lead to diminishing 
returns (Dahlander et al., 2016). Companies need the absorptive capacity to integrate new 
knowledge and technology. Greco et al. (2016) indicated several authors found that 
specific OI strategies have a positive effect on economic and industrial innovation 
performance. However, Greco et al. argued over-search and over-collaboration might 
reduce the benefit of OIs marginal returns when a business leader engages with many 
external innovation partners. Greco et al. conjectured that many external innovation 
channels (search breadth) used by a leader, the extent to which the leader’s firm engages 
with the external channels (search depth), and the extent to which a leader of a firm 
collaborates through different external channels (coupled OI) is curvilinearly related with 
innovation performance. 
There is a ceiling to the level of new information that employees can master. Qi 




assimilation that employees in a firm can process. Furthermore, the speed at which this 
knowledge saturation point is reached is influenced by the quantity of information and 
the degree of difference between the new information and the existing knowledge of the 
employees in the firm. Once the maximum level of new knowledge is reached, more 
information can lead to a reduced chance of developing breakthrough innovations (Qi 
Dong & McCarthy, 2019). As leaders increase the number of external relationships 
innovation performance increases up to a point and then innovation performance 
diminishes with the addition of more external relationships. Too many projects started 
without the absorptive capacity to manage the projects, will lead to failure.  
In addition to absorptive capacity, managers should consider their firms’ industry 
and business environment before engaging in OI practices. Naqshbandi (2018) indicated 
that firms’ organizational characteristics are important to OI implementation. In this 
regard, Naqshbandi et al. (2019) contended that leaders in the pharmaceutical industry 
chose licensing, mergers, and acquisitions, and external collaborations while adopting OI. 
Firm leaders use these modes of OI engagement based on their organizational 
characteristics, such as size, age, market orientation, and industry type. 
Naqshbandi (2018) highlighted that most of the firm’s organizational 
characteristics are related to OI and these attributes determine how the firm’s managers 
engage in OI. Naqshbandi (2018) research has practical implications and provides 
insights to managers regarding the firm, industry, market, and ownership characteristics 
that are favorable towards engagement in OI. Naqshbandi (2018) showed that leading 




mergers and acquisitions, and external collaborations while adopting OI. Naqshbandi 
(2018) identified how firm leaders that engage in OI in different industries differ in their 
organizational values, such as internal integration and external adaptation. External 
adaptation andinternal integration are the core challenges leaders of organizations need to 
overcome for their organizations to remain viable. Naqshbandi (2018) findings indicated 
that firm leaders’ in the computer, electronics, and pharmaceutical industries focused 
more on internal integration and external adaptation, while most leaders in the aerospace 
industry placed less importance on internal integration and external adaptation. Managers 
of firms considering OI strategies should be careful in choosing the appropriate model of 
innovation for their firm’s organizational characteristics to attain a competitive market 
position. 
It is important for leaders to choose the appropriate OI model to be successful. 
Managers of firms need to identify their OI model based on their industry, market and 
ownership characteristics (Naqshbandi, 2018). While OI may aid leaders in enjoying a 
competitive market position through the elimination of traditional barriers, an 
inappropriate choice of the OI model may lead a firm towards unfavorable outcomes 
(Bican et al., 2017). Strategically, using OI correctly is important for an organization’s 
success while implementing this business model.  
Governance. 
 Managers implementing OI strategies must decide on a proper governance 
model. Hosseini et al. (2017) suggested OI governance refers to the establishment and 




performance. Organizations use the internal processes to manage OI more efficiently and 
effectively since it has been shown that OI management influences the effect of OI in 
performance (Musawir et al., 2020; Uribe-Echeberria et al., 2019). Leaders of 
organizations must decide when to use specific OI strategies (e.g. partnerships, 
innovation contests, and communities) and closed forms of innovation (e.g. authority-
based and consensus-based hierarchy) (Hewitt-Dundas & Roper, 2018). Aligned with 
Hosseini et al., Bican et al. (2017) posited that using the proper governance for OI is a 
success factor. Different governance models may be better for some projects but not 
others and different governance models require distinct approaches to project 
management and selection.  
By selecting the correct innovation implementation strategy, organizational 
leaders can enhance their followers’ speed and efficacy of new knowledge assimilation 
and utilization and subsequently intellectual property right choices, (e.g. patents, 
copyrights, or trademarks). Bican et al. (2017) raised awareness of such innovation 
management challenges within R&D processes, as well as strategic intellectual property 
management by multiple parties. OI models have porous firm boundaries that result in 
less proprietary control and increased coordination costs, requiring a joint evaluation of 
OI and intellectual property (Foege, et al., 2019; Lauritzen & Karafyllia, 2019; Vilas, 
Lopes, & de Carvalho, 2018). Researchers refer to the balance between OI 
implementation and managing the intellectual property as the OI paradox. 
With OI, managers depend on collaborations with innovation partners external to 




governance-related issues, such as OI decision making, roles and responsibilities, partner 
relationship management, and managing intellectual property (IP) (Hosseini et al., 2017; 
Mi & Feng, 2019). The governance-related issues are also linked to managing the 
absorptive capacity of the firm, a critical success factor. Clear management processes 
help managers work more efficiently. 
Klarner et al. (2019) multiple-case study of four pharmaceutical companies 
revealed a sequential process of board members' involvement in governance. Klarner et 
al. (2019) discovered directors with expertise govern scientific innovation, followed by 
the full board’s involvement in its strategic aspects. Klarner et al. (2019) noted the extent 
of director involvement varied across board levels in terms of the direction (proactive or 
reactive), timing (regular or spontaneous), and the extent of formality of exchanges 
between directors and organizational members. Scholars have argued that directors’ 
knowledge and expertise is a prerequisite for effective board involvement in the strategy. 
Mi and Feng (2019) findings suggest the board of directors is the main decision-maker in 
business activities and the larger the board membership the less efficient decision-
making. Inefficient decision-making tends to lead to reduced innovation because of a 
decline in the efficiency of communication among board members. Furthermore, Klarner 
et al. contend that the director's human capital is important for governing a multifaceted 
and long-term strategic issue such as innovation, which can be defined as the adoption of 
new ideas, whether it be a new product, process, service, technology, or practice. 
Klarner et al. (2019) research revealed that two elements constitute board 




differentiated involvement, characterized by knowledge exchanges that changed in their 
direction, timing, and formality. Klarner et al. findings indicated directors shared their 
human capital with several executives and employees at the lower ranks, and the lower 
ranks provided information on company-specific innovation activities. Second, the full 
board monitors and provides advice through controlled involvement, characterized by 
unidirectional knowledge exchanges with fixed timing and formality. Klarner et al. 
findings indicated directors were involved in innovation from the early research stage of 
idea generation and testing to the more advanced innovation stage of implementation.  
Moreover, according to some research, middle managers are vitally important to 
OI processes and activities for their ability to smooth the absorptive capacity of the firm. 
Rafique et al. (2018) research suggested the importance of role specificity of middle 
managers to smooth absorptive capacity processes. The role specificity of middle 
managers aligns with Hosseini et al. findings that official roles and responsibilities can 
help managers with managing the absorptive capacity problem. Rafique et al. research 
indicated that middle managers with little absorptive capacity are often pulled in many 
directions diverting their attention and making them less effective. Undoubtedly, defining 
the roles and responsibilities of the managers can help lessen this burden on managers by 
better defining their roles and available resources.  
In addition to defined roles and responsibilities, the governance of OI projects 
need well-defined processes for the assignment of IP evolving from OI collaborations. 
Toma et al., (2018) used a single-case study of R&D intensive firms to investigate how 




of R&D intensive firms tend to engage in OI processes with various research partners, 
such as customers, suppliers, and employees, and therefore these firms require 
Intellectual Property (IP) strategies to protect their IP. For this reason, proper IP 
protection strategy should use all the available tools, such as registered and unregistered 
IP rights (patents, copyrights, trademarks, non-disclosure agreements (NDA)) (Bican et 
al., 2017; Biswas & Akroyd, 2016; Brunswicker & Chesbrough, 2018; Toma et al., 
2018).  
Similarly, Hosseini et al. suggest that IP is very important to the OI business 
model and conceded the more open a business is the more challenging it is to protect its 
IP. Leaders sharing selective information with OI partners are rewarded through an 
improvement in the quality of returned information (Barchi & Greco, 2018). Therefore, 
organizational leaders need the ability to balance and selectively define the optimal 
amount of information to disclose. Brunswicker and Chesbrough (2018) researched OI at 
the project level and their findings suggest the careful design of openness, in terms of 
knowledge sharing and IP control, the formalization of processes, and the role of top 
management, play a significant role in managing OI at the project level. 
In contrast to Brunswicker and Chesbrough (2018), Toma et al. (2018), and 
Hosseini et al. (2017), Oltra et al. (2018) suggest that a lower degree of formalization and 
higher decentralization makes inbound, outbound, and coupled OI more effective at 
influencing positive firm performance. Oltra et al. (2018) argued that formalization is a 
moderating variable that decreases the effect of OI on performance. Further, the effect of 




integration across functions and hindering creativity, collaborative learning, and 
flexibility (Oltra et al., 2018). Pharmaceutical leaders who emphasize open 
communication also nurture an environment that is conducive to team member 
innovation.  
Biswas and Akroyd (2016) similar to Brunswicker and Chesbrough (2018), Toma 
et al. (2018), and Hosseini et al. (2017), suggested the stage-gate process is a common 
control mechanism used for project management and suggested that a hybrid stage-gate 
open innovation process may assist managers with the co-development of new products. 
The hybrid stage-gate open innovation process indicated a process that is a hybrid of a 
formalized process with less decentralization. Biswas and Akroyd (2016) posited it is 
important to examine the governance of interfirm co-development projects in an OI 
context to determine the optimal model for governance. Biswas and Akroyd (2016) 
argued the stage-gate process can enable the development of trust and cooperation which 
supports the co-development relationship. Biswas and Akroyd's (2016) study findings 
imply that a stage-gate process can be a flexible governance mechanism, which leaders 
can adapt over time in relation to the needs of the co-development partners in an OI 
setting. 
Methods. 
Hosseini et al., (2017) suggested to be successful with open innovation (OI) 
projects, leaders need to have well-defined methods and processes for knowledge 
exploration, retention, and exploitation. Additionally, methods that help to facilitate 




relationships (Olk & West, 2020). Processes that encourage social interactions may aid in 
improving the probability of innovation. Leaders need to consider ways to promote social 
interactions within the project teams as they develop processes to manage and enhance 
OI.  
Toma et al. (2018), and Biswas and Akroyd (2016) encouraged managers to 
develop processes that provide some degree of control over the innovation process. 
Processes that provide control over the innovation process are in contrast to Oltra et al. 
(2018) assertion that formalization of processes hinders the innovation environment 
because it obstructs the free flow of information. The stage-gate hybrid method suggested 
by Biswas and Akroyd (2016), is possibly a logical compromise that may help manage 
the process of OI without limiting the innovator's creativity.  
 External collaborations are of great importance to the implementation of OI 
projects. Cheng et al. (2019) highlighted the importance of relationships external to the 
organization and suggested collaborations between leaders of firms are positively related 
to the effectiveness of the outcomes of OI projects. External collaborations are one of the 
most important requirements of a firm for carrying out its OI business transactions as the 
external collaborators are the ones, who support OI in varied instances (Olk & West, 
2020). Cheng et. al. defined collaborators as the competitors, partners, and even the 
suppliers, who are responsible for enhancing the knowledge of the firm's leaders and 
employees in a variety of ways. The social interactions with these external collaborators 




Furthermore, Cheng et al. (2019) studied the impact of the organizational learning 
capability of a firm on the manager's implementation of OI. Cheng et al. concluded OI is 
a business model, that incorporates not only the internal but also the external 
organizational factors associated with the organization of the firm for the purpose of 
attaining competitive advantage and sustaining the advantage in the target market. In this 
context, Cheng et al. concluded that organizational learning capability plays a significant 
role in maintaining a proper learning environment in the workplace to enhance the 
knowledge and awareness of the management and employees regarding their work 
process. Leaders who cultivate the organizational learning capability may improve the 
efficiency level and maximize the performance of the company as a whole. Cheng et al. 
suggested organizational learning capability is positively related to the effectiveness of 
the outcomes of open innovation. 
Moreover, Cheng et al. (2019) research demonstrated that knowledge is 
enormously important to a firm. Cheng et. al suggested knowledge is one of the primary 
resources for any organization to innovate or to gain a competitive advantage. The 
majority of leading companies invest a large number of resources on the process of 
knowledge sharing as the entire work process depends on the knowledge that is shared 
not only within the firms but also with the external firms such as the customers (Bican et 
al., 2017). The large investment in knowledge sharing between firms may result in more 
successful innovation outcomes. 
Cheng et al. (2019) concluded that OI includes the different aspects that an 




of time. These factors are mostly comprised of the three elements specifically knowledge 
sharing within and outside the firm, the inclusion of external collaboration/partnership, 
and lastly the proper implementation of the organizational learning capability within the 
operational procedures. The knowledge sharing within and outside the firm undoubtedly 
support ensuring that the outcomes of OI are highly effective concerning the 
organizational learning capability i.e., and creation of a learning environment within the 
workplace.  
Moreover, with the increase in the amount of knowledge sharing between leaders 
and employees within and outside the firms, the effectiveness of OI practices rise. Cheng 
et. al. suggested a second factor that focuses on external collaborations results in positive 
impacts due to the inclusion of external partners such as the supplier firm’s managers and 
employees. The inclusion of external collaborators increases the effectiveness of the OI 
strategy.  
To ensure compatibility between partnering firms, leaders should select the right 
partner. Leaders should select partners with similarities in approaches, priorities, and 
processes that are beneficial for external relations (Bican et al., 2017). Furthermore, 
partner similarity with regard to knowledge, organizational arrangements, institutional 
frameworks, or physical distances, support OI, and shared learning. As a source for new 
knowledge, networking supports the commercialization of internal knowledge and is 
regarded as a key characteristic of OI firms. Methods of networking include the 
placement of technology scouts, co-funding activities at incubators, and the creation of 




Bican et al. (2017) suggested that individuals’ tendencies to prefer collaboration 
with existing partners often leads to decreased external networking capabilities. 
Consequently, these leaders can miss out on new opportunities and new external 
partnerships. To overcome the complexity of integrating new partners and binding 
intellectual property arrangements, leaders foster networking capabilities through the 
formation of transaction-light partnerships (Bican et al., 2017). The transaction-light 
partnerships involve non-essential development areas and standard intellectual property 
protection contracts. The transaction-light partnerships are intended to support the 
building of relationships between the leaders of collaborating firms without significant 
commitment. Leaders can use transaction-light partnerships to mitigate the risk of 
engaging in external relationships.  
Some leaders establish separate internal business groups to manage OI projects. 
The establishment of separate OI business groups improves the utilization of internal and 
external knowledge and resources. The efficient use of resources by a separate internal OI 
business group can help leaders manage the absorptive capacity.  
Managers can expand their firm’s reach and increase the probability of their 
company innovating by developing external alliances. Martinez, Zouaghi, and Garcia 
(2017) demonstrated expanding a firm's boundaries by engaging in external alliances can 
enhance the internal R&D efforts. Martinez et al. suggested little is known about how 
managers can operationally leverage the potential benefits of OI to create an innovative 
advantage. Hosseini et. al. proposed the OICF to potentially help managers implement 




the leader of the organization will need to account for contextual factors. Further research 
should thus focus on specific capability areas considering contextual factors e.g. industry, 
size, etc. 
Fisher and Qualls (2018), through the lens of the knowledge perspective of 
interfirm OI, posited that managers of firms should source, screen, evaluate, acquire, and 
leverage external knowledge resources for their innovation processes. Fisher and Qualls 
(2018) assert OI necessitates an external focus and greater consideration to coordinating 
the use of external knowledge. Similar to Hosseini et al. (2017) OICF, Fisher and Qualls 
(2018) suggested managers may need systematic methods for capturing the knowledge 
that they discover as they scan the external environment. Effectively capturing 
knowledge is a capability that enables managers to be more aggressive at leveraging 
external knowledge. Leaders using interfirm OI practices attempt to manage the 
combination of internal and external knowledge to create new products. 
Furthermore, Fisher and Qualls (2018) suggested that proponents of the 
knowledge perspective emphasize the company's external search processes to actively 
seek, identify, and gather novel ideas to improve new product design and development. 
Similarly, Hosseini et al. (2017) described the need for knowledge exploration, retention, 
and exploitation in the OICF. Fisher and Qualls (2018) posited knowledge search is often 
conceptualized in terms of breadth, which is the number and range of different types of 
external channels of information. Also, knowledge search is frequently described in terms 
of depth, which is how deeply the firm utilizes the different external knowledge sources. 




such as the number of innovations and product innovativeness. Fisher and Qualls (2018) 
suggested advocates of the knowledge perspective of interfirm OI recognize that the 
method by which the knowledge output is shared is critical to achieving success. 
Advocates of the knowledge perspective view explain how freely available external 
knowledge can be internalized by firms in their efforts to develop new products, and how 
the internal knowledge that is accumulated by firms can be externalized through various 
channels. 
Fisher and Qualls (2018) also viewed OI through the relationship-based 
perspective of interfirm open innovation. The relationship-based perspective of interfirm 
OI advocates cooperation with external leaders of firms similar to the OICF proposition. 
Interfirm relationships are critical to discovering, sharing, internalizing, and leveraging 
the external knowledge that is central to interfirm OI (Fisher & Qualls, 2018). The extent 
that managers can access, and leverage knowledge depends on how they interact with 
external partners. A leader of a firm’s position in an innovation network influences 
effective collaborative relationships. 
Accelerators and science parks. A limitation of the OICF is that it does not 
address a leader's use of accelerators and science parks. These strategies are in their 
nascent stage therefore, these strategies have not been thoroughly researched. The 
accelerators and science parks are recent methodologies for knowledge exploration, 
retention, and exploitation. Richter et al. (2018) suggested corporate accelerators are 
organizational strategies intended to bring together leaders of innovative new ventures 




financial resources of established companies (Richter et al. 2018). A leader’s objective 
for the use of an accelerator program is to open the innovation process and actively profit 
from the innovative capacity of new ventures.  
Richter et al. (2018) posited that an accelerator program functions as a 
performance filter, which excludes likely failures early in the innovation process. The 
uncertainty, exploration, and ambiguity usually associated with innovation are reduced 
through the application of strict processes, assessment criteria, and decision points within 
the corporate accelerator program. A corporate accelerator program provides well-
defined conditions supporting managers in keeping the creativity of startups under 
control and directed in the interests of the firm. Richter et al. suggested an established 
company can extract innovations from the creative and enthusiastic participants, who 
often originate from a wide range of educational and industrial environments. Leaders 
implementing corporate accelerator programs provide a controlled environment away 
from the functional management of the firm. Richter et al. conceded there is little 
empirical data to support the corporate accelerator program strategy although the concept 
sounds feasible.  
Science technology parks (STPs) emerged from the relationships among the 
leaders of universities, industries, and governments (Robaczewska et al., 2019; Silva et 
al., 2020). Encouraging the cooperation of leaders in university-industry to promote 
innovation and increase innovation performance is one of the most important strategies of 




the 1980s. The STP concept was called the Marshallian district (Scaringella & 
Radziwonb, 2018).  
The Marshallian district is based on economies of scale achieved by leaders of 
firms (Scaringella & Radziwonb, 2018). A high degree of industrial localization offers 
good opportunities to achieve economies of scale and reduce costs (e.g. STPs) (Silva et 
al., 2020). Furthermore, the reduction of resistance has a positive impact on reducing 
transaction costs. Leaders can use an industrial district to divide tasks, jobs, and value 
chain activities among local small and medium-sized enterprises (SMEs). In a defined 
setting (e.g. science park), small and medium-size firms benefit from knowledge 
spillovers (disclosures). The combination of colocation, limited transaction costs, and 
high specialization are important elements of the Marshallian districts (Scaringella & 
Radziwonb, 2018). The STP is a strategy that leaders may use to collocate near firms 
with employees with many different capabilities. 
Information Technology 
 Hosseini et al. (2017) posited that information technology is very important for 
knowledge search, retention, and exploitation as viewed through the lens of the OICF. 
Hosseini et. al. emphasized the need for collaborations and sharing of information to 
effectively implement OI strategies. IT is a tool that can be used to facilitate the 
collaboration process and information sharing (Ettlinger, 2017; Bican et al., 2017; 
Milutinović et al., 2017; Matricano et al., 2019). Sharing information is needed externally 




Information technology (IT) capability assists leaders of firms to acquire, transform, and 
leverage external knowledge.  
Leaders can leverage IT to search for new knowledge. Information technology 
(IT)-enabled knowledge exploration may include environmental scanning techniques 
such as search platforms like the pharmaceutical company Lilly’s InnoCentive 
crowdsourcing platform, or advanced data mining tools that help search web pages, the 
scientific literature, and global patent databases for relevant ideas and technologies 
(Carter et al., 2017; Christensen & Karlsson, 2017; Cui et al., 2015; Gkypali et al., 2017; 
Ettlinger, 2017). Von Briel and Recker (2017) suggested examples of successful OI 
initiatives found in the literature range from idea gathering to online user innovation 
communities. Also, managers of organizational innovation networks combine participant 
resources to generate ideas in the early stages of the innovation process to facilitate 
successful later stages of development. 
 Crowdsourcing is another IT tool that leaders can use to elicit ideas for a variety 
of stages in the innovation process (Ettlinger, 2017; Jespersen, 2018; Stroh, 2019). The 
internet has helped to decentralize the drug discovery process which has become a more 
bottom-up process. Crowdsourcing is one tool that has made it possible to search for 
ideas at a lower cost (Carter et al., 2017; Ettlinger, 2017; Jespersen, 2018; Stroh, 2019). 
Carter et al., suggested pharmaceutical company leaders typically establish their Internet 
portals to solicit solutions from community participants. GlaxoSmithKline (GSK) and 
Bayer are examples of pharmaceutical companies that have an Internet portal for 




leaders may use specialist brokers who have crowdsourcing platforms such as 
NineSigma, or Kaggle (Gillespie et al., 2019). Participants from crowdsourcing platforms 
have been credited with providing relevant input into ten drug discovery projects at Bayer 
e.g. Grants4Targets (Carter et al., 2017). Carter et al., suggested Boehringer Ingelheim 
leaders’ have pursued several crowdsourcing projects with InnoCentive that ranged from 
studying new translational models of psychiatric disease to new approaches for the in 
vivo modulation of gene expression in lymphocytes.  
Notwithstanding this scientific progress, some researchers still argue that OI may 
not be an effective innovation strategy. Von Briel and Recker (2017) argued that OI in its 
many forms is not necessarily an effective strategy. Practices that have been identified in 
successful implementations of OI do not necessarily prevent failures. Leaders' OI failures 
are supported by ample research and so the need for an effective implementation 
framework (Ettlinger, 2017). Indeed, these idea-generating platforms suffer from one 
major drawback, innovation requires that a creative idea be reduced to practice in the 
form of an actionable plan (Matricano et al., 2019). The process of converting an idea 
into action is an iterative process that needs to be collaborative and free from restrictions 
(Stroh, 2019). Von Briel and Recker (2017) provide executives in organizations seeking 
to establish online OI communities with a set of managerial lessons learned and a 
framework with checkpoints and guidelines. Von Briel and Recker (2017) posited several 
potential barriers to consider before beginning an online community: (a) Industry context, 




Commitment, and (f) Participant community. All these barriers are critical to evaluate 
before initiating an online OI community.  
Von Briel and Recker (2017) demonstrated how the successful implementation of 
an online OI community depends on several interrelated conditions and that these 
implementations often face unique challenges associated with the context of the business. 
While the generalization of the Von Briel and Recker (2017) findings is limited because 
of the single case study design, their approach provides an unusual opportunity to learn 
from failure. Von Briel and Recker (2017) posited there is little known about OI failures 
or the reasons for OI failures. Some prominent examples of OI failures include Boeing, 
LEGO, and some pharmaceutical implementations. Perhaps studying the causes of these 
failures could help business leaders avoid these implementation pitfalls.  
The underlying reasons for the innovation failures in these leaders’ companies 
were related to strategy, communication, and a lack of knowledge of the complexity and 
intricacies of using open innovation strategies. The LEGO managers' primary mistake 
which led them to failure was producing products the customers did not want. LEGO 
management had lost sight of the needs of their customers. Organizations have 
traditionally relied solely on internal knowledge to drive innovation (closed innovation). 
However, such closed innovation limits the flow of ideas and can perpetuate negative 
groupthink. When the LEGO leaders realized a need to reconnect with their customers 
the LEGO managers launched a program to engage users in the development of products 




  The LEGO managers used an open innovation strategy that encouraged 
customers to interact, share, and vote for ideas regarding the kinds of products or services 
they would like to see LEGO develop (Cina & Cummings, 2018). The crowdsourcing 
platform the LEGO managers implemented was called ‘Cuusoo’ (Japanese for ‘wish’) 
(Cina & Cummings, 2018). The LEGO managers, opening lines of communication with 
customers in this way, improved engagement with their growing customer base and their 
future product developments came to be informed by the user community. This open 
innovation strategy brought the company into greater sync with industry trends and 
customer needs. The LEGO company has come to be recognized as a world leader in toy 
innovation with high levels of growth and posting a record profit of $1.87 billion in 2016 
(Cina & Cummings, 2018). 
Boeing experience another example of the difficulty in implementing OI. Boeing 
managers needed a better adaptation of organizational and development practices to the 
innovation introduced by their decisions (Shenhar et al., 2016). The Boeing management 
team experienced difficulties developing its highly innovative Dreamliner aircraft. The 
Boeings Dreamliner engineers’ first major challenge involved designing the aircraft’s 
body using light-weight composite materials. The Dreamliner aircraft was to 
accommodate 250 passengers on long-haul transportation for about a 20% lower fuel cost 
(Shenhar et al., 2016). This change in the material was necessary for fuel savings.  
Although composite materials were not new, the composite materials were never 
used in such a large aircraft (Shenhar et al., 2016). The Dreamliner engineers required 




fuselage (Shenhar et al., 2016; Tidd & Bessant, 2018). The engineers' lack of experience 
with the composite materials resulted in having to redesign the plane, which significantly 
delayed the Dreamliner project.  
Boeing managers’ confidence in its experience and record of success led project 
leaders to believe that the new project would be as successful as others. The engineers 
probably underestimated the challenges and scope of innovation (Shenhar et al., 2016; 
Tidd & Bessant, 2018). The managers' difficulties were a result of the following major 
challenges: (a) the use of newly developed technologies, (b) outsourcing a large extent of 
design to numerous, less experienced subcontractors, (c) a new business model of 
revenue sharing, and (e) a new assembly model (Shenhar et al., 2016). Using these 
strategies, Boeing managers helped retain competitive positioning by taking advantage of 
modern technologies, and practices, but Boeing managers’ execution was less than 
optimal. 
Procter & Gamble (P&G) provided another example of an OI failure. The 
managers made a strategic mistake in trying to implement OI. P&G managers did not 
understand the complexity and intricacies of using open innovation strategies. P & G was 
an early adopter of the OI strategy so there was not as much research available to guide 
the managers. The P & G case study provided some of the learnings for implementing OI. 
The P & G managers decentralized the firm’s research and development (R&D) to 
shift P&G’s R&D to an OI model (Han et al., 2019).The P&G managers’ OI model 
shifted the burden of innovation from a centralized department to business units 




innovators with focus and increased success rates for new product introductions, these 
products did not address the unmet needs of the customers. The focus of the managers 
was on the invention of new technology and not addressing the unmet needs with 
innovation (Han et al., 2019). In P & G’s case, there were flaws in both the strategy and 
the implementation, which ultimately led to failure. 
The open innovation strategy led to organizational decentralization and reduced 
collaboration between separate product groups within P & G (Han et al., 2019). This 
change failed to utilize one of P&G’s competitive advantages, its conglomerate structure. 
For instance, the innovators of Crest Whitestrips used bleaching technology from the 
laundry business, glue technology from the paper products business, and film technology 
from the food wrap department (Han et al., 2019). P & G’s centralized R&D allowed 
these departments to work together to inspire innovation.  
Furthermore, the compensation structure of the business unit managers also 
contributed to the failure of the R&D reorganization because the managers were being 
rewarded for business unit profitability (Han et al., 2019). Since R&D expenditure 
lowered profits over the period, investment was not initiated unless it led to an immediate 
profit, offsetting revenue growth, and rewarding managers for incremental improvements 
in the products. This led to the transition from high-risk, high reward products to 
incremental improvements of existing products. Shorter development periods and quicker 
return on investment became the priority. 
P & G re-established distinct R&D departments that pooled knowledge from 




2019). Furthermore, the managers started looking outside the firm for needed capabilities. 
Scientists, engineers, and product developers across all P&G’s product lines were given 
specific long-term targets and budgets with a significant portion of compensation derived 
from qualitative metrics. This new system emphasized long-term decision making 
through focused planning and was flexible enough to reward employees for visionary 
innovations (Han et al., 2019). A similar compensation structure was implemented at 
Johnson & Johnson with great success. 
In contrast to Von Briel and Recker (2017) findings, Gillespie et al., (2019) 
suggested that some sectors have embraced the paradigm shift to open innovation. 
Gillespie et al., (2019) noted there is an increased uptake of OI practices by leaders of the 
biopharmaceutical sector. Leaders in biopharmaceutical firms have embraced OI models 
to optimize drug development. Gillespie et al., (2019) suggested the leaders of the 
traditional proprietary, non-collaborative biotechnology, and pharmaceutical companies 
are increasingly using principles, processes, and structures of OI to increase drug R&D 
effectiveness and efficiency. Gillespie et al., (2019) distinguishes three essential elements 
in the successful creation of OI partnerships: (i) culture, (ii) collaborative management 
skills, and (iii) strategic capability alignment. Gillespie et al., (2019) three essential 
elements are three of the six high-level factors that Hoesseini et al., (2017) identified in 
the OICF proposal.  
Gillespie et al., (2019) provided guidance for business leaders and scholars 
interested in the managerial and strategic dimensions of applying OI to the drug 




all six factors of the OICF may lead to more effective implementations. Leaders' use of 
OI has the potential to improve quality, increase speed, and lower costs, and thus yielding 
positive benefits for global health. 
People 
Hosseini et al. (2017) said employees and corporate OI teams play an essential 
role in OI. Important capabilities that can foster innovation performance are technology 
mastery, personal peer leadership, and capabilities to link to external organizations 
(boundary-spanning). The latter capabilities do not need to be held by all individuals. 
However, leaders need to ensure there is a sufficient number of individuals placed in the 
correct functions or dedicated teams that have these capabilities. Martinez et al. (2017) 
posited that knowledge, skills, and abilities used by individuals in an organization, 
determine a firm's potential gains from collaborating with external organizations. Many 
researchers’ findings have highlighted the importance of the employee’s knowledge, 
skills, and abilities for the successful implementation of OI.  
Consistent with Hosseini et al. (2017) and Martinez et al. (2017), Kratzer et al. 
(2017) suggested there is an agreement that the people are central to a company’s 
innovation process and drive the innovation process. Kratzer et al. posited employees in 
companies perform innovation in an environment with rules and regulations that might 
support or hinder innovation. The OI paradigm expects leaders of companies to engage in 
external relationships for innovation. Leaders often neglect to cultivate a culture of 




Creating an internal culture of openness is important for leaders considering OI 
strategies and before collaborating with external partners. Kratzer et al. (2017) argued 
that establishing internal openness (unhindered communication) is important before 
collaborating with external partners. The key challenges in building and developing an 
innovation culture are the changes in the organization's approach and mobilizing teams to 
bring products and services to the market quickly. The leader's fundamental challenge 
with this process is that companies need to incorporate a view on innovation shared not 
only by the company leaders but also by employees (Hannena et al., 2019).  
Incorporating a view of innovation shared by the company leaders and employees may 
require a significant culture change driven from the top down.  
Leader and employee behavior and attitudes are important elements in shaping a 
corporation's work culture and innovation culture. Kratzer et al. (2017) argued employee 
behavior and attitudes are linked with cultural thinking. Employees' behavior and 
attitudes are important elements in shaping a corporation's work culture and innovation 
culture (Hannena, et al., 2019). Employee behavior and attitudes may facilitate the OI 
process. Leaders considering using OI to enhance their internal innovation process need 
to put several OI supporting processes in place to facilitate the implementation. Some of 
the areas that leaders need to focus on to be successful include strategy alignment, 
governance, OI methodology, employees, corporate OI teams as well as the firm’s culture 
(Hosseini et al., 2017; Kratzer et al., 2017). To be successful, leaders of a firm need to 
take a holistic approach when implementing OI to ensure their overall strategy is in 





Hosseini et al. (2017) suggested a different mindset is imperative for OI. 
Employees currently working in a closed innovation practice will need to change their 
practices concerning managing ideas, knowledge, and technologies. Leaders’ and 
employees’ cultural values and beliefs are critical for OI as are formal practices, which is 
why leaders of organizations must implement an innovation culture that enables and 
promotes OI activities (Mahdad et al., 2020). Hosseini et al. said related competencies are 
OI attitude and behavior, risk attitude toward OI, and attitude toward IP management. 
Not-invented-here syndrome. One challenge for leaders implementing OI is 
shifting employee mindset from a closed to open innovation. As organizational leaders 
shift strategies, the leaders need to consider ways to overcome the not-invented-here 
(NIH) syndrome (Hannena, et al., 2019). NIH syndrome is an employee’s negative 
attitude toward external knowledge exploration. Leaders need to develop strategies to 
change the employees’ attitudes to be accepting of the external knowledge exploration 
strategy (Hannena, et al., 2019). The failure of leaders to mitigate the NIH syndrome may 
lead to a biased and incorrect evaluation of external ideas and technologies. Biased and 
faulty evaluation of external ideas and technologies by managers could result in the 
ineffective implementation of OI. 
Not-connected-here attitude. Related to NIH, another barrier that leaders need to 
overcome is the not-connected-here attitude, which reflects a negative employee attitude 
toward external knowledge retention, e.g., attributable to a lack of trust in innovation 




lack of trust in external partners can have a negative impact on information exchange 
with the external partner. Both the NIH syndrome and the not-connected-here attitude 
hinders the exchange of information with innovation partners (Hosseini et al., 2017). 
Risk-taking tolerance. Employees suspicious of the leaders’ intentions for 
external sourcing may consider external sourcing as a greater risk given a higher level of 
perceived uncertainty compared with internal sourcing. Leaders being too risk-averse and 
attempting to minimize risk by implementing too many risk filters may slow down the 
innovation progress, potentially leading to missed opportunities and potentially leading to 
failed collaborations. Leaders implementing OI need to encourage an entrepreneurial 
culture tolerant of risk-taking to benefit from OI. 
Leadership commitment. The level of leadership commitment and attention 
impacts the effectiveness of the OI strategy. Leaders must create a work climate 
conducive to OI. The articulation of goals and top-down encouragement involves written 
and spoken communication (Musawir et al., 2020). Leaders’ OI success stories can be 
used to inspire employees to actively search outside of an organization for new ideas and 
technologies. By implementing the proper incentives, leaders can foster employees’ 
engagement throughout different OI activities. Leaders should consider incentives that 
foster acquiring innovation from external sources. Providing incentives to employees for 
acquiring innovation from external sources can support an employee's mindset in 
abandoning an NIH attitude. 
Governance-related culture change. The culture change must entail not only 




legal and IP leaders must be encouraged to adopt a positive attitude supportive of OI. 
Instead of taking an excessive protective position, legal and IP leaders should encourage 
employees to seek mutually beneficial agreements (Moellers et al., 2020). Sharing 
knowledge with innovation partners or communities can be beneficial as the quality of 
returning information improves with the amount of initially revealed information (De 
Silva & Rossib, 2018). If managers convey an overprotective attitude to employees, this 
may lead employees to avoid external engagement given the perceived personal and 
professional risks of the unplanned disclosure of information. 
Hosseini et al. posited that culture affects innovation success but concluded that 
no specific OI culture exists. Nestlea et al. (2019) suggested extant research has found 
superior innovation performance of firms located in research clusters. It was unclear if the 
superior innovation performance was a result of the proximity of the firms, or other 
unknown factors (Nestlea et al., 2019). Nestlea et al. concluded that more research was 
needed to determine if the differences in the open innovation culture was the result of 
membership in a cluster. Similarly, Hosseini et al. concluded more research is needed 
regarding OI-enabling culture.  
The high-impact organizational changes related to OI involve the adoption of 
cultural changes and new approaches to the entire company governance and innovation 
processes. The spread of an open innovation culture within organizational boundaries 




Pharmaceutical Industry and OI Implementation 
Pharmaceutical company leaders have been experiencing challenges to bring 
novel therapeutic agents through the R&D process to generate a sufficient return on 
investment (DiMasi, et al., 2016). The cost estimate to bring a new drug to the market 
averages $2.9 billion and 13 years (DiMasi et al., 2016). Leaders in the pharmaceutical 
industry have trouble discovering and developing novel therapeutics. Chesbrough and 
Chen (2015) suggested pharmaceutical drug development costs have risen over the past 
20 years but the number of new molecular entities (NMEs) approved has not increased.   
As pharmaceutical companies reduce their R&D spending significantly to balance 
their budgets, unmet medical needs will remain unaddressed (Chesbrough & Chen, 2015; 
Gillespie et al., 2019; Gkypali et al., 2017; Masuccia et al., 2020; Reichman & Simpson, 
2016). Much of the rising costs in drug development can be traced to work on failed 
projects that are abandoned before getting to market (Chesbrough & Chen, 2015; 
Reichman & Simpson, 2016). Improving the efficiency of R&D may allay the costs and 
potentially lead to more therapeutics for a variety of conditions. Hosseini et al. reported 
there is evidence that OI strategies can increase the net present value of projects by 70% 
compared to closed innovation projects. Leaders using OI strategies are associated with 
superior firm performance and higher innovative activity in both large and small-to-
medium-sized companies (Battistella et al., 2017).  
OI is a broad term for diverse strategies that managers use to seek external input 
and public engagement and has become an essential tool with researchers, who are 




sourcing to address some of the most pressing problems in medicine. Notable examples 
of such open drug development include initiatives formed around malaria and tropical 
disease (Weng et al., 2018). Currently, there is no established OI framework for the 
pharmaceutical industry that pharmaceutical leaders can use as a guide for the 
implementation of OI projects.  
Searching for strategies to improve the drug discovery process, leaders in the 
biomedical research field are beginning to embrace OI. Shaw (2017) noted traditional 
drug development models are perceived as inefficient, with the cost of research and 
development continuing to rise even as production of new drugs stays constant. Shaw 
(2017) noted the changes in leaders’ strategies are starting to reshape the industry. OI 
practices have found their way into the drug discovery process, from target identification 
and compound screening to clinical trials. Shaw (2017) argued the OI perspective poses 
some risks-which include the management of collaboration and the protection of 
proprietary data but in many cases, OI strategies are a more efficient and ethical way to 
conduct biomedical research. In the pharmaceutical industry, practical limitations, 
cultural norms, and intellectual property (IP) concerns have resulted in a development 
process traditionally conducted in a carefully protected proprietary environment often 
referred to as closed innovation.  
Consistent with Shaw (2017), Banerjee and Siebert (2017) studied the effect of 
pharmaceutical and biotech R&D leaders’ collaborative business relationships on the 
firms’ research activities and drugs offered on the market. Banerjee and Siebert (2017) 




their R&D pipelines and eliminate similarly aligned research projects. Managers 
streamlining R&D can reduce costs and eliminate drug candidates that could potentially 
limit the profits of each product. Late-stage R&D collaborations formed among leaders of 
larger firms increase a firm’s research activities but reduce the number of drugs launched 
in the product market. Leaders reduced the number of drugs launched in the product 
market by eliminating overlapping drug products. Some researchers have highlighted that 
R&D collaborations between leaders of companies have helped overcome innovation 
obstacles and resulted in an increase in R&D activities. Banerjee and Siebert (2017) 
studied leaders' strategies who were engaged in R&D collaborations throughout the 
different stages of the drug development process from early to late stages.  
Engaging in R&D collaborations at all stages of the R&D process can help 
leaders manage the increasing cost of R&D. Banerjee and Siebert (2017) studied firms 
where leaders engage in R&D collaborations to manage the increasing costs of drug 
development. Banerjee and Siebert's (2017) findings revealed that early and late-stage 
R&D collaborations have differential impacts on the technology and product markets. 
More specifically, early-stage collaborations allow firms to increase R&D activities that 
may eventually be transmitted to the product market and lead to an increase in the 
number of drugs offered on the market.  
In contrast, when leaders engage in late-stage R&D collaborations among larger 
companies, leaders have less of an impact on a firm's R&D activity. Late-stage products 
are less likely to need an intense R&D effort than early-stage products. Research 




socially and ethically beneficial impacts such as avoiding wasteful duplications in 
research. In the pharmaceutical industry, findings from several research studies indicated 
leaders engaging in R&D collaborations increase the probability of developing new 
drugs. R&D collaborations allow the leaders to exploit the synergy effects and share the 
costs of R&D. 
 Developing and exploiting innovation activities in collaboration with external 
parties requires new decisions that should be delineated in when, how, with whom, with 
what purpose and in what way (Battistella et al., 2017; Carter et al., 2017; Namkuk et al., 
2015). West and Bogers (2017) said inbound OI practices are more commonly used than 
outbound practices in the pharmaceutical industry. Few researchers have studied the 
outbound OI practices in the pharmaceutical industry. Yet, even with the extensive OI 
research that has been performed, there are still many areas that remain unexplored and 
warrant more research such as the use of outbound OI. 
Open Innovation Capability Framework 
This research project is intended to identify a potential OI implementation 
framework for OI projects that pharmaceutical managers can use to engage in OI 
projects. The research on OI implementation is sparse and fragmented. Few researchers 
have attempted to identify the factors that may support the successful implementation of 
OI. OICF comprises the outside-in and coupled OI processes and provides a 
comprehensive overview of related capabilities compared to many of the other studies. 
The holistic approach of the OICF can assist decision-makers in prioritizing, selecting, 




(2017)posited that leaders of organizations should carefully analyze the relevance of the 
OICF distinct capability areas in their context (e.g. industry, environment, and size).  
OICF 
While compiling the OICF, Hosseini et al. focused on keeping the included 
capability areas as OI-specific as possible. Henceforth, the OICF captures specific 
capability areas, but not necessarily unique to OI (Hosseini et al., 2017). The OICF 
framework provides practitioners with a framework to further explore open innovation. 
Hosseini et al. posited that most research on OI frameworks focuses on single facets of 
OI. The OICF framework introduced by Hosseini et al. only covers two modes of OI, the 
outside-in and coupled processes of OI. The OICF framework takes several of the 
proposed theories and merges them for a more comprehensive implementation 
framework.  
Hosseini et al. (2017) collected the data through a literature review of OI theories 
and integrated them into a larger OICF theory that takes pieces from all the theories used 
to explore OI. Subsequently, Hosseini et al. validated the assumptions with a 7-point 
Likert scale survey using academia and industry OI experts. One shortcoming of the 
proposed OICF is that Hosseini et al. did not address the inside-out model of OI where 
leaders sell unused technology or abandoned compounds for financial gain.  
Inside-out model 
 The inside-out model may be an effective OI mode for the pharmaceutical 
industry and is only beginning to be researched (Chesbrough & Chen, 2015). Toma et al. 




but conceded that pharmaceutical leaders engaging in OI may have to differentiate their 
IP protection tools depending on the R&D phase. The development of therapeutic agents 
goes through several stages before being a marketed product. 
Additional OI framework 
Battistella et al. (2017) explored the different practices, actors, and tools adopted 
for opening the innovation process by small and medium-sized companies facing 
difficulties in OI implementation. Battistella et al. discovered 23 practices, 20 actors, and 
11 tools used in the OI processes of small and medium-sized companies. Battistella et al. 
methodology used to develop the framework are consistent with the methodology 
Hosseini et al. used to develop the OICF. Both researchers searched the literature and 
identified the different OI practices and tools used to develop the proposed frameworks to 
implement OI.  
Few researchers have studied the implementation of OI projects. Battistella, et al. 
(2017) suggested previous research of OI studied management challenges for effective OI 
implementation, yet there was still little research on putting OI into practice and therefore 
a need to study OI implementation.  Battistella et al. reported that other researchers 
introduced frameworks that support managers in identifying the OI practices that best fit 
a specific innovation project. Battistella et al. studied different combinations of variables 
related to OI practices e.g. access mode and variables related to a company’s innovation 
context in terms of knowledge channels. Battistella et al. concluded, similar to Hosseini 




knowledge and create competitive businesses. Identifying and engaging in external 
relationships to acquire new capabilities are important to the implementation of OI. 
Most empirical investigations about OI have been case studies of successful early 
adopters of open innovation, and their analyses have mostly been at the company level. 
Inbound OI involves a wider variety of actors and tools than outbound OI practices 
(Battistella et al, 2017). OI practices such as crowdsourcing, external networking, and 
scouting from external sources involve the use of external sources of knowledge through 
the application of two to three different tools (Battistella et al., 2017). Consistent with 
Hosseini et al. (2017) proposed OICF, the tools used for targeting, sourcing, and 
acquiring valuable knowledge involved the use of IT.   
Project level antecedents 
Namkuk et al. (2015) suggested that future research needs to look at the project 
level implementation of open innovation (OI). The project level is where the innovation 
begins in R&D (Battistella et al., 2017). Namkuk et al. explored systematic relationships 
between various antecedent factors and the degree of openness. Project-level openness 
could be affected by team and task characteristics, such as team size, learning distance, 
strategic importance, technology, and market uncertainty, and relevance to the main 
business. Namkuk et al. collected data from 303 companies in Korea to identify the 
antecedents that affect inbound and outbound openness. The Namkuk et al. findings 
suggested six factors at the project level that could be expected to affect OI behaviors.  
Subsequently, Namkuk et al. (2015) conducted an exploratory field study to learn 




teams that already possessed sufficient capabilities to succeed on their own did not 
engage in OI. Project leaders of teams should consider their teams' knowledge and 
capability gap (learning distance) as an antecedent of open innovation.  
Furthermore, Namkuk et al. (2015) suggested one of the most critical resources 
for an R&D project is human resources, and so team size is used as a measure of the 
number of employees available to a team. Accordingly, the amount of resources available 
to a team is expected to affect its OI activities. Advocates of the social capital perspective 
inferred that opportunities to form relationships with external parties grow as team size 
grows; therefore, larger teams are more likely to benefit from more sources of external 
resources than smaller teams.  
Five design principles 
Five design principles posited by Ollila and Ystrom (2016) were (a) presence of 
participants equals influence, (b) diversity is the source of creativity, (c) multiple 
identities of participants created an extended view, (d) a higher purpose unites the 
participants, and (e) the participants are creators of the collaboration. Ollila and Ystrom 
(2016) noted practitioners should discuss the expectations and preconceptions when 
engaging in collaborative activities and the practitioners benefit by using the design 
principles to facilitate the communications. The themes emphasized by Ollila and 
Ystrom, (2016) are closely related to the six factors postulated by Hosseini et al. (2017).  
Limited scope framework 
Ya Juan Wu et al. (2016) performed a single case study using an ethnographic 




Identifying potentially suitable drug candidates to fit the product portfolio is a very small 
but important aspect of inbound OI. Ya Juan Wu et al. used a grounded approach like 
Ollila and Ystrom (2016) to let the themes discovered by the researchers inform their 
theory. Although Ya Juan Wu et al., research was very limited in scope their findings 
discovered principles closely related to some of Hosseini et al. (2017) open innovation 
capability framework (OICF).  
Conclusion 
The OI paradigm has received an extensive number of contributions from 
different researchers that studied a variety of OI dimensions such as strategy, leadership, 
and organizational structure. Inbound OI practices seem to be more prevalent than 
outbound practices and not a lot of research has been performed on outbound OI 
practices. Furthermore, researchers suggested that more research is needed at the project 
level in different contexts. Also, OI researchers suggest organizational leaders need a 
more comprehensive OI implementation framework. Currently, the approach to OI 
implementation is fragmented because little research has been dedicated to this topic.  
The OI approach to innovation has become very important for innovation and 
technology and therefore captured the attention of managers and other leaders. These OI 
practices of organizing research, development, and innovation activities could be an 
effective way of sharing knowledge, obtaining complementary assets, and generating new 






In Section 1, I provided the foundation for this study and discussed the basis of 
the problem and the purpose of the study. The conceptual framework provided a path to 
understand how pharmaceutical leaders implement OI drug development projects, and the 
significance of the study supports the purpose statement. Also, in Section 1, I introduced 
the research question for the study. In the review of the literature, I analyzed and 
synthesized various sources of literature to achieve an in-depth analysis as it relates to the 
research topic. 
In Section 2, I explain the role of the researcher, participants, chosen research 
method and research design, sampling method, ethical research, data collection 
instrument, techniques for data collection, data organization techniques, and data 
analysis. At the end of Section 2, I detail aspect of reliability and validity as it applies to 
qualitative research and describe the rigor of my qualitative research. 
Section 3 comprised research findings, how the findings apply to professional 
practice, implications for social change, the recommendations for action. I conclude 
Section 3 with my recommendations for future research, a discussion of the foundation of 






Section 2: The Project 
In Section 2, I discuss my role as a researcher and describe my study participants. 
This is followed by a description of the qualitative research method and single case study 
research design. I describe the population and sampling followed by a discussion of 
ethical research. Section 2 also includes discussion of data collection instruments, data 
collection techniques, data organization techniques, and data analysis. I conclude Section 
2 by explaining my strategies for improving the rigor of my research. 
Purpose Statement 
The purpose of this qualitative single case study was to explore strategies US 
pharmaceutical company leaders used for developing and implementing OI R&D 
projects. The targeted population was five US pharmaceutical R&D directors in one 
pharmaceutical firm who have successfully used OI strategies to develop and implement 
R&D drug development projects. The firm was headquartered in the northeastern region 
of the US. My research findings may enhance US pharmaceutical leaders’ capacity to 
increase ROI, decrease operational costs, and positively influence local communities 
through increased tax revenues. Furthermore, efficient discovery and production of novel 
therapies may lead to a better quality of life for many patients. 
Role of the Researcher 
The role of the researcher is central to the data collection process. The researcher 
needs to be aware of how their role in research is significant. In this qualitative research, I 
was the data collection instrument and played a vital role in understanding the practices 




refrain from being judgmental while remaining focused and attentive. Furthermore, my 
responsibility was to conduct ethical research following the Belmont Report. The 
Belmont Report provides researchers with a set of ethical standards and guidelines they 
must adhere to for the protection of participants. My role was to interview five 
participants from one company, collect and analyze data, and manage interviews while 
protecting the privacy of participants. I used semistructured interviews with 10 open-
ended questions that addressed significant areas of the OICF. I used an interview protocol 
to help maintain consistency in data collection between participants. 
Transparency in terms of the researcher’s position, potential biases, and 
assumptions is vital in terms of judging accounts of qualitative research and the 
authenticity of findings. I have no direct professional relationship with participants 
involved in the study; however, I work for the same employer. Participants are 
geographically located in the northeast of the US. Also, participants work in a different 
department at a higher pay grade than myself.  
I worked in biomedical R&D for over 36 years and played an integral role in 
managing in vivo research and research facilities within public and private organizations 
in New York. Because of my years in biomedical research, I needed to be aware of 
potential biases. Confirmation bias occurs when the researcher filters participants’ 
information and uses a subset of the information according to the researcher’s preexisting 
beliefs (Gatlin et al., 2017; Reid et al., 2018). Confirmation bias makes people more 




practicing reflexivity while interviewing can avoid these biases (Pessoa et al., 2019). I 
mitigated confirmation bias via reflexivity and questioning of my conclusions. 
Participants 
I used purposive nonprobability sampling to select participants for this research 
study. Nonprobability sampling is appropriate for qualitative research. The purposive 
sample consisted of participants who possessed the knowledge to contribute relevant 
information regarding strategies for developing and implementing OI R&D projects. 
Researchers using nonprobability sampling rely on their judgment when choosing 
members of the population to participate in their study. Some types of research design 
require researchers to decide which individual participants would be most likely to 
contribute appropriate data, relevance, and depth. 
The research participants selected possessed the experience and ability to 
contribute relevant information regarding developing and implementing OI R&D projects 
and agreed to be audiotaped. To gain access to participants, I requested organizational 
cooperation to assist in identifying relevant participants. I sent a letter of organizational 
cooperation (see Appendix A) to the company’s human resources and legal departments 
to get permission to do research. After I received pharmaceutical organization and 
Walden University Institutional Review Board (IRB) approval, I sent a recruitment letter 
(see Appendix B) via email to participants to request their participation. Participants who 
agreed to be interviewed were sent consent forms (see Appendix C) with the IRB 




Before interviewing participants, I received affirmative consent forms from their 
email addresses. I needed to select a minimum of four participants. Gaya and Smith 
(2016) said three participants are enough for a single qualitative case study design. 
Creating a systematic and transparent way of obtaining participants is beneficial to 
providing adequate information for a qualitative single case study (Benoot et al., 2016). 
After data saturation was achieved, I determined the number of participants needed for 
the study was five participants. Sim et al. (2018) said determining a qualitative sample 
size a priori is problematic. Qualitative case studies do not have a set number of 
participants in terms of sample size, but when data saturation is reached, more 
information will no longer bring value to the study (Boddy, 2016). The initial set number 
I determined for this study was four participants, but after collecting data, data saturation 
was achieved with five participants.  
Transcripts and audio recordings will be stored for 5 years so that only I have 
access to the data. Consent to participate in the study was obtained from each participant 
before conducting each interview. Sending consent forms in advance for participants to 
review expedited the process of using the data for this doctoral study. Raw data is 
important to save from interviews. Data will be stored on a flash drive, my computer, and 
on cloud management software (OneDrive). All stored data will be password-protected 
and retained for a minimum of 5 years after the study’s completion. 
Research Method and Design 
The research method used for this study was qualitative, and the research 




nature of the topic, which involved strategies US pharmaceutical company leaders used 
for developing and implementing successful OI pharmaceutical R&D projects. The 
qualitative research method and the single case study design were appropriate for this 
study because they can increase researchers’ understanding of a contemporary 
phenomenon with the use of multiple data sources from a single organization and not 
multiple organizations (Yazan, 2015; Yin, 2018). 
Research Method 
When conducting a research study, three research methods are available for 
researchers to use qualitative, quantitative, and mixed methods. The choice of the 
research method is related to the research problem and purpose (Bloomberg & Volpe, 
2019). Qualitative research involves the use of multiple data sources to discover patterns 
or themes under given circumstances (Kegler, et al., 2019; Merriam &Tisdell, 2016). 
Qualitative data sources include interviews, observations, and company documents. 
Quantitative research involves the use of instruments to accumulate data for statistical 
analysis to test a theory or hypothesis (Bryant et al., 2018). The quantitative research 
method was not appropriate for this study because it requires the examination of multiple 
numerical variables, which was not the emphasis of this study. Mixed-methods research 
combines both qualitative and quantitative methods (Bloomberg & Volpe, 2019). 
Because the mixed methods approach uses the quantitative method, it did not provide the 
information needed for this study, thus making it unsuitable for this research. A 
qualitative research method was the most appropriate method for this study because the 




Kegler et al. (2019), the qualitative research method helps us understand the context, 
explore new phenomena, identify new research questions, and helps to construct a 
complete description of the themes or patterns relevant to the phenomenon. 
Research Design 
A single case study research design was the research design used for 
this study. A single case study research design aligns with the qualitative process that 
deals with exploring a phenomenon thoroughly in real circumstances to establish 
connections that are not easily seen but are important to understanding the phenomenon 
(Ganz & Ayres, 2018). The tools I used for data collection were interviews and publicly 
reported company documents. A single case study research design incorporates real 
situations to collect data from a variety of sources, which highlights a conclusion or set of 
conclusions (Merriam &Tisdell, 2016; Yin, 2018). The single case study was most 
appropriate for this study because I was exploring one organization by interviewing five 
R&D directors to gain knowledge on strategies US pharmaceutical company leaders used 
for developing and implementing successful OI pharmaceutical R&D projects. My 
comprehensive analysis of the specific business problem provides strategies for 
developing and implementing successful OI pharmaceutical R&D projects.  
Researchers may also use other qualitative research designs for a study, including 
ethnography, narrative inquiry, and phenomenology. Ethnographers focus on studying 
human society and culture (Merriam & Tisdell, 2016). Ethnography was not suitable for 
my study because my intention was not to focus on studying a group of people within a 




story form. Biography, life history, and autobiography are examples of narrative inquiry 
(Merriam & Tisdell, 2016). The narrative inquiry was not appropriate for my research.  
The main purpose of the phenomenology design is to explore human experiences 
from the perspective of participants within a phenomenon (Bloomberg & Volpe, 2019). 
Studying human experiences was not my intent for this study. The objective of my study 
was to explore strategies US pharmaceutical company leaders used for developing and 
implementing successful OI pharmaceutical R&D projects. Therefore, a single case study 
design was the most appropriate design for this study. 
Population and Sampling 
The population sample for this qualitative single case study was five R&D 
directors in a single US pharmaceutical company located in the northeast. Participants of 
the qualitative single case study included male and female R&D directors who were 
chosen through purposeful sampling and were interviewed via WebEx. The choice of 
interview method was to make the participant comfortable during the interview and to 
transcend geographical barriers. Purposeful sampling is a standard technique used in 
qualitative research studies where a researcher selects information-rich cases for the 
study that will provide insight and understanding to a phenomenon or topic of interest 
(Benoot et al., 2016). The conditions for selecting participants in this study included 
R&D directors in a single pharmaceutical company with knowledge and experience with 
using OI strategies to implement pharmaceutical R&D projects.   
In qualitative research, data saturation is important. Fusch and Ness (2015) 




and that data gathered must be rich quality data and a dense quantity of data. Saunders, et 
al. (2018) posited that data saturation is commonly taken to indicate that, based on the 
data that has been collected or analyzed, further data collection and/or analysis are 
unnecessary. Data saturation is met when there is no new data being collected, no new 
patterns being discovered, and no new coding being conducted (Tran et al., 2016). In a 
qualitative research study, once data saturation is met, the sample size will be set. In this 
study, I interviewed five participants to ensure data saturation. I ensured data saturation 
for this study by collecting comprehensive data and identifying essential themes of the 
open innovation capability framework (OICF) by interviewing five participants who are 
R&D directors and have met the study conditions. Saunders, et al., (2018) concluded that 
saturation should be consistent with the research question (s), the theoretical position, and 
the analytic framework adopted for the study.   
Ethical Research 
Throughout the research process, I focused attention on the application of ethics 
to the research process. Sobočan et al. (2019) said ethics when viewed broadly are 
intrinsic in the research process, from the decision about what to study and how to study 
it, through data analysis and dissemination of the research findings. The principles of the 
Belmont Report such as autonomy, beneficence, and justice were maintained through 
informed consent, non-deception, the prevention of psychological or physical harm, 
privacy, confidentiality, and a commitment to collecting and presenting accurate research 
findings. The three major components of the Belmont Report (respect for persons, 




 Each participant enrolled in my study signed a written consent form (see 
Appendix C.) to take part in the interviews which is the data collection phase of the 
research. Moreover, I followed the protocols of the Belmont Report and ensured that the 
study participants had a full understanding of their part in the study. I provided a copy of 
the consent form before the data collection to allow participants time to review the form 
and understand the study. Nusbaum et al. (2017) said potential participants should be 
provided a copy of the consent form before or after the consent meeting, which they will 
receive via email. Nusbaum et al. argued participants supported this commonly used 
approach because it provided individuals with more time to read the consent form.  
Privacy and confidentiality were further protected by coding the interview 
sessions with all participants and organizations. Coding the interview sessions will 
protect the identity and confidentiality of all participants. Researchers have the 
responsibility of conducting ethical research and safeguarding the confidentiality of all 
participants (Miracle, 2016). Participant names and identifiers will be saved in an 
EXCEL file under a coding system to guarantee confidentiality. 
Participants were informed that they may withdraw from the study at any time 
without penalty. The time and location of the interviews were at the convenience of the 
participants. Each participant interview was given an allotted time of 1 hour, but time was 
increased or decreased depending on the responses given by each participant. Participants 
were able to disengage from the interview at any time without consequences by 




For participants that provided interviews a twenty-five-dollar Amazon gift card 
was provided for their time. Kelly et al. (2017) conducted an experiment with a nationally 
representative sample to test the impact of different incentive types and amounts on 
willingness to participate in a qualitative interview. Kelly et. al. study findings suggested 
increased participation with incentives as low as twenty-five dollars. Researchers may 
increase the study participation by providing a least the minimum incentive. 
Each research study comes with its own set of specific ethical issues and in this 
case, the study was conducted at my employer. The participants do not report to me and 
are also at a level above my pay grade. Furthermore, the participants were located hours 
from my current location, so I do not know them personally. The data from the study is 
stored on OneDrive and my personal computer. All data storage will be password 
protected and saved for five years. 
The participating research site signed a letter of organizational cooperation 
permitting participation (see Appendix A). Once the IRB approved the study, I sent 
invitations to the study participants through email and answered any questions the 
participants had about the research. All participants read and signed an informed consent 
form before the interviews. 
Data Collection Instruments 
The primary data collection instrument for the study was the researcher. I used 
semistructured interviews for data collection. A well-designed semistructured interview 
should ensure data are captured in key areas while still allowing flexibility for 




The interviews for this research consisted of 10 open-ended questions, which were 
intended to uncover the viewpoints and experiences of five pharmaceutical R&D 
directors with experience successfully developing and implementing OI pharmaceutical 
R&D projects. 
I used a voice recording device to document the interviews with each participant. 
Heath et al. (2018) suggested recording interviews, then transcribing the interviews 
verbatim, and storing the interviews as a word document for analysis. Recording 
interviews, then transcribing the interviews verbatim facilitate accurate data collection. 
All data files were anonymized and stored securely. 
After the completion of each interview, I had the voice recording transcribed. 
Member checking was performed by emailing the interview transcripts, interpretations of 
the data from the interview, and the conclusions of the data from the interview to the 
participants. Marshall and Rossman (2016) proposed member checking can be used to 
improve the accuracy and validity of the interview data. The follow-up interview process 
included the participants’ evaluations of my understanding of the interview discourse for 
accuracy.  
Along with accuracy the reliability and validity of the data collection instrument 
were improved through this member checking process. Furthermore, public company 
documents and other external website content were used in the data collection process to 
corroborate the data collected with interviews. Bloomberg and Volpe (2019) suggested 
the combination of interview data with public company documents and external website 




Upon the approval of the study from the Institutional Review Board (IRB), I 
emailed an invitation to potential participants along with an informed consent form 
clarifying the risks and benefits of participating in the study. I was also available to 
answer any questions the participants had about the study. The allotted time for each 
interview was approximately 1 hour, but more or less time was needed depending on the 
participant’s responses. The interviews were conducted via WebEx (synchronous 
computer-mediated communication). Merriam and Tisdell (2016) proposed synchronous 
computer-mediated communication will help overcome the geographical barrier of 
participants and researchers. 
 The participants for this study were several hours away so the use of synchronous 
computer-mediated communication made it more cost-effective and timelier to collect the 
data. Lo Iacono et al., (2016) suggested synchronous computer-mediated communication 
is a system that provides users with a way to send voice and video across the internet via 
a synchronous (real-time) connection. The use of this technology provided convenience 
because the interviews of participants at a distance were conducted without the expense 
of travel. The time for the interviews was at the convenience of the participant. Another 
advantage of the synchronous computer-mediated communication was that a venue did 
not need to be secured. All the participants answered the same 10 interview questions 
(Appendix D), which helped to explore the experiences of each participant in answering 
the central research question. The data obtained helped uncover themes that 
pharmaceutical R&D directors have experienced while successfully developing and 




After each interview, I transcribed, coded, and analyzed the data. The data 
collected from the interviews are stored in a computer file on OneDrive cloud storage, a 
USB flash drive, and my computer hard drive and will be saved for 5 years. Each device 
is password protected and only I have access to the data. After 5 years, I will destroy the 
flash drive along with any other resources and documents. Data collection was essential 
to gathering the relevant data needed to answer the principal research question “What are 
the strategies that US pharmaceutical company leaders use to develop and implement 
open innovation R&D projects? 
Data Collection Technique 
Researchers can gather case study evidence from many sources. Yin (2018) 
proposed that interviews, documentation, and archival records are three sources of data 
that can be used for case study research. This qualitative case study included the data 
collection instruments of semistructured interviews, public company documents, and 
external website content intended to uncover the viewpoints and experiences of 
pharmaceutical R&D directors with experience successfully developing and 
implementing open innovation (OI) pharmaceutical R&D projects. Belotto (2018) 
suggested semistructured interviews allow the researcher to ensure that the same core 
information is elicited from each participant while providing the flexibility to probe more 
deeply into the rich descriptions of experiences that participants share.  
I used the following procedure to schedule the semistructured interviews.  
For each participant, I scheduled a date and time for each interview based on the 




questions about their experiences in successfully developing and implementing OI 
pharmaceutical R&D projects. The 10 interview questions were asked via synchronous 
computer-mediated communication with the five pharmaceutical R&D directors in a 
single pharmaceutical company. Each interview was allotted one hour; however, more or 
less time was needed depending on the responses of the participants. The interviews 
included a question on what strategies the pharmaceutical R&D directors used to develop 
and implement OI pharmaceutical R&D projects. The interviews of each participant were 
via synchronous computer-mediated communication (e.g. WebEx) and their responses 
were recorded using a digital voice recorder. Also, for confirmability and to use 
methodological triangulation I collected data from public company documents and 
external website content relevant to the research question.  
The analysis of the data collected uncovered strategies that could help 
pharmaceutical R&D directors develop and implement open innovation (OI) 
pharmaceutical R&D projects more efficiently. Data collection techniques have 
advantages and disadvantages for qualitative research studies. Doody and Noonan (2013) 
posited advantages include (a) gaining insight and context on the topic, (b) gaining an 
understanding of a topic from a participant’s experience and knowledge, and (c) gaining 
useful information for the research study. The disadvantages of collection techniques 
include (a) intrusiveness to the participant, (b) time-consuming to both participant and 
researcher, (c) expensive data collection methods, and (d) may be susceptible to bias.  
Once I received approval from the Institutional Review Board (IRB), the 




collected from the participants of the study. Initial contact was made with the participant 
to clarify any questions or concerns they may have about the study and the informed 
consent form. The informed consent form was collected through e-mail. I scheduled the 
interviews and then interviewed the participants via synchronous computer-mediated 
communication. Upon completion of the interviews, the data voice files were transcribed 
and shared with the participants to confirm the accuracy.  
Member checking is the process by which participants check and approve the 
understanding of the researcher of the data collected from the interview (McGrath et al., 
2019). I performed member checking with the participants after the interviews. If the 
participants made any changes to the transcription, I notated the changes on the initial 
transcript. I then imported the transcript into the data analysis software. Yin (2018) 
suggested computer-assisted tools can help analyze qualitative data. The computer-
assisted tool can help novice researchers code and categorize large amounts of data 
(Saldana, 2016). I used data analysis software to help identify themes and categories from 
the data.  
Data Organization Technique 
The organization of data was a critical aspect of examining and understanding 
data in the study. The iterative inspection and organization of data are necessary in a 
qualitative case study (Castleberry & Nolen, 2018). I was the primary data collector of 
information from each participant of the study. I classified each participant by a letter and 
number, which will be documented and coded in a Microsoft Excel spreadsheet for 




coding system for each participant (Clark & Vealé, 2018). The data collected were 
recorded, examined, transcribed, and stored on OneDrive (cloud storage), a flash drive, 
and my personal computer. All devices are password protected and only I have access to 
the data. To safeguard the rights of participants, confidential data can be secured and 
stored (Clark &Vealé, 2018). After 5 years, I will destroy the flash drive along with any 
other resources and documents used in the study. 
Data Analysis 
Qualitative case study methodologists can use up to six sources of evidence for 
their research including documentation, archival records, interviews, direct observations, 
and physical artifacts (Yin, 2018). The major strength of the case study research is the 
opportunity to use multiple sources of evidence. I conducted a qualitative single case 
study, which included participant semistructured interviews, public company documents, 
and external website content. Fusch et al., (2018) suggested case study researchers should 
use multiple sources of data to improve the quality of their research. Data triangulation 
adds depth to the data that are collected. Yin (2018) posited that there are no set guides to 
use to begin analyzing qualitative data, therefore, all data analysis of the single case study 
should use a broad analytic approach. Castleberry and Nolen (2018) suggested a model of 
qualitative data analysis outlined in five steps: compiling, disassembling, reassembling, 
interpreting, and concluding. 
The qualitative data analysis is an iterative process and preferably should be 
performed concurrently with data collection (Miles et al, 2020). Miles et al. (2020) 




and generating strategies to collect new data. Miles et al. presented three streams of data 
analysis (a) data condensation, (b) data display, and (c) findings and verification. After 
each interview, I transcribed the data and familiarized myself with the interview 
transcript.  
Raskind et al. (2019) suggested many researchers used verbatim transcripts as the 
primary data source. I created a matrix using the 10 interview questions and the responses 
from each participant to get started. Raskind et al. reported that 20% of researchers 
reported using matrices during analysis. Matrices were used to compare codes or themes 
across participants (Raskind, et al., 2019). I manually went through the transcripts to 
identify similarities and differences between participants and then tried to identify themes 
from the participants' responses. 
Next, I uploaded the transcripts into a computer-assisted software program (e.g. 
NVivo ) to help identify themes to understand the data and generate codes. After 
collecting relevant content from company documents and external websites I followed 
the same iterative process to identify themes. These main themes provided strategies 
pharmaceutical R&D directors have used to successfully develop and implement OI 
pharmaceutical R&D projects. 
The purpose of the data analysis was to uncover themes that can answer the 
research question of this qualitative single case study. Discovering the topical similarities 
and differences could potentially inform the answer to the overarching question. The data 
analysis process of a qualitative study is an important step. Saldana (2016) suggested 




analysis. I used 23 codes from the OICF and some keywords identified during interviews 
with participants to begin coding the interviews. To provide direction and organization to 
the data analysis I used the 23 codes that compose the high-level categories of the OICF 
to begin my analysis. Researchers need to analyze data to uncover significant patterns 
and themes that answer the main research question of the qualitative study (Yin, 2018). I 
consolidated the data collected into sections similar to the sections in the literature review 
related to the OICF framework: strategic alignment, governance, methods, IT, people, 
and culture.  
I used NVivo, a qualitative data analysis software, to help organize and code the 
data analysis in this study. Researchers can use software like NVivo to identify patterns 
and themes in the data that may otherwise be overlooked (Davidson et al., 2017). 
Davidson et al. (2017) suggested NVivo helps researchers to see into the depths of a 
qualitative research project. The strengths of using the NVivo software included working 
with very rich text-based and/or multimedia information, where deep levels of analysis 
on small or large volumes of data were required. I used the NVivo software to verify the 
patterns and themes uncovered through the manual analysis of the data and the sections 
described in the literature review. The connection between the methodology, the 
literature review, and the findings of the study is the OICF. I used the OICF as the lens to 
analyze the data.  
Reliability and Validity 
The significance of a qualitative research study is contingent on the level of 




methodologists ensure trustworthiness in a case study approach by demonstrating 
credibility, confirmability, transferability, and dependability (Yin, 2018). Trustworthiness 
in qualitative research includes both the validity and reliability dimensions (Quintão et., 
2020). The following sections provide information on the use of case study procedures in 
a qualitative research study. 
Reliability 
Reliability refers to how qualitative methodologists will address the dependability 
of the study results. Some of the ways a qualitative methodologist enhances the 
dependability of a study are member checking of data interpretation, transcript review, 
using an interview protocol, and reaching data saturation. Qualitative researchers produce 
findings not derived using statistical procedures or other means of quantification. Cypress 
(2017) posited qualitative researchers use naturalistic inquiry to understand a 
phenomenon in a context-specific setting. A qualitative research methodologist does not 
attempt to manipulate the phenomenon of interest.  
Qualitative research methodologists ensure reliability based on consistency and 
care in the application of research practices. In this qualitative study, I followed the 
interview protocol for each participant to ensure each participant was asked the same 
questions. Furthermore, the participants had experience developing and implementing 
open innovation (OI) pharmaceutical projects. To establish trust and confidence in the 
findings of the research, rigor will be necessary to confirm the consistency of the study 
methods. Reliability and validity should be taken into consideration by qualitative 




(Belotto, 2018). The foundation for the reliability of the research study is determined 
through the dependability of the research process, which included the research question, 
data collection method, data interpretation, and the instrument (me).  
Merriam and Tisdell (2016) suggest that reliability in research design is based on 
the assumption that there is a single reality and studying repeatedly will yield the same 
results. In addition to the semistructured interviews of the five participants, I used 
documentation to methodologically triangulate the data collected from semistructured 
interviews, and finally, I performed member checking after each interview to ensure the 
accuracy of the results.  
Dependability 
When researchers follow research procedures, they improve the consistency of 
data collection. When the audit trail of a researcher is duplicated by another researcher, 
dependability will occur (Connelly, 2016). I ensured dependability by having participants 
check the information gathered through member checking and confirm the accuracy of 
my understanding. Gaus (2017) explained member checking is a participant’s validation, 
which confirms the data, interpretations, and conclusions of the researcher with the 
interview participant. Member checking is imperative and a common way to ensure the 
truthfulness and authenticity of the data (Fitzpatrick, 2019). I performed member 
checking after each interview to confirm my understanding. 
Validity 
The qualitative research methodologist seeks to ensure validity by establishing 




findings. Validity consists of two types of validity, internal and external (Fitzpatrick, 
2019). Gaus (2017) posited internal validity is the extent to which the findings can be 
interpreted accurately and in a qualitative study, internal validity is most important. 
Sound internal validity is established by using multiple sources of data collection (e.g. 
interviews, document analysis, etc.) and interviewing multiple sources of people and 
triangulating their stories within the case (Gaus, 2017). An assessment of data by the 
researcher for consistency among the participants of the study will help achieve internal 
validity within the qualitative research study (Yin, 2018).  
Qualitative methodologists can use purposeful sampling in qualitative research so 
that the participants are the appropriate people to respond to the intent of the research. 
Fitzpatrick (2019) suggested that purposeful sampling requires the selection of 
participants who know about the research topic. I collected information from multiple 
sources, which included conducting interviews, company documents, and external 
website content to address validity.  
The interviews conducted by me were consistent for all participants using an 
interview protocol (Appendix D). Furthermore, I will improve internal validity with the 
use of member checking and triangulation. Member checking is the process of seeking 
participant validation and the most important way to rule out the possibility of 
misinterpreting the meaning of the participants' interviews (Gaus, 2017). Member 
checking was an important way of identifying my biases and misunderstandings of what I 
heard. Furthermore, to increase the credibility of the findings and reduce bias, researchers 




different sources of data, multiple qualitative methods, or multiple researchers (Gaus, 
2017). 
Credibility 
Credibility is an accurate and truthful portrayal of a participant’s lived 
experience (Cypress, 2017). The credibility of the study is assurance in the truth 
of the findings. A qualitative research methodologist can enhance credibility by 
member checking of the data interpretation, participant transcript review, 
triangulation, and an interview protocol (Gaus, 2017). Demonstrating qualitative 
credibility ensures the reviewers that the researcher addressed the findings from 
the perspective of the participants (Fitzpatrick, 2019). I improved the credibility of 
this study with participant transcript review, member checking, triangulation, and 
an interview protocol.  
Confirmability 
A qualitative research methodologist can enhance the confirmability by 
ensuring that the results can be confirmed or supported by others. The researcher 
may conduct member-checking with study participants to ensure confirmability 
(Belotto, 2018). Confirmability is the degree findings are consistent and could be 
repeated. This is analogous to objectivity in quantitative research. Qualitative 
researchers keep detailed notes of all their decisions and their analysis as it 
progresses (Connelly, 2016). 
 I asked probing questions during interviews and followed up with 




ensure confirmability. Data saturation was obtained in this qualitative single case 
study by interviewing five participants until no new themes were evident. The 
sample size of this qualitative single case study was determined when data 
saturation was met (Fusch et al., 2018). I made sure the sample size was 
sufficient to reach data saturation and address the research question.  
Transferability 
The nature of transferability is the extent to which the findings can be 
useful in other contexts. The reviewers of qualitative research determine the 
applicability of a researchers’ findings to their circumstances (Bloomberg & 
Volpe, 2019). Qualitative methodologists can support the study’s transferability 
with a rich, detailed description of the context, location, and people studied (Yin, 
2018). Qualitative researchers need to provide a vivid picture that will inform 
and resonate with the reviewers (Amankwah, 2016).To improve the 
transferability of the findings I meticulously adhered to the data collection and 
analysis techniques for the research design, used an interview protocol and 
ensured I reached data saturation. Furthermore, I used a notebook to document 
my thoughts, reflections, and decisions regarding the study to further improve 
the ability to make the study transferable. 
Transition and Summary 
In Section 2, I described how I conducted a qualitative single case study to 
explore strategies US pharmaceutical company leaders use for developing and 




semistructured synchronous computer-mediated communication interviews to collect data 
and explore the experiences and strategies of the participants. In addition to 
semistructured interviews, I reviewed public company documents and other external 
website content to triangulate data. I used purposeful sampling to select five R&D 
directors in a single US pharmaceutical company located in the northeast. Before the 
collection of data proceeded, I obtained permission from Walden University’s IRB to 
execute data collection. Once transcriptions of interviews were complete, I used NVivo to 
uncover common themes and patterns in the study. Also, I explained the purpose 
statement, role of the researcher, population and sample size, research method and 
design, ethics, data collection instrument and techniques, data analysis, and the reliability 
and validity of the study. In Section 3, I incorporate the presentation of findings, 
applications to professional practice, implications for social change, recommendations for 







Section 3: Application to Professional Practice and Implications for Change 
Introduction 
The purpose of this qualitative single case study was to explore the strategies that 
US pharmaceutical company leaders use to develop and implement OI R&D projects. 
Five R&D directors in a US pharmaceutical company located in the northeast who had 
successfully implemented OI strategies were interviewed via NVivo. The five R&D 
directors discussed four major themes: OI roles and responsibilities, business and OI 
strategy alignment, leadership attention, and OI decision making. 
Presentation of the Findings 
The overarching research question in this study is: What are the strategies that US 
pharmaceutical company leaders use to develop and implement OI R&D projects? I used 
pseudonyms to anonymously identify the five participants as P1, P2, P3, P4, and P5. Four 
major themes emerged during data analysis to indicate strategies US pharmaceutical 
company leaders use to develop and implement OI R&D projects. The following 
discussion is organized around these four themes (see Table 1).  
OI is an established approach to improve innovation performance, but many 
organizational leaders have unsuccessfully embedded strategies permanently in their 
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Frequency of Major Themes for Each Participant 
Themes 
 
P1 P2 P3 P4 P5 
OI roles and 
responsibilities 




16 44 3 15 23 
Leadership 
attention 
20 28 6 12 21 
OI decision 
making  
22 31 4 11 13 
 
OI Roles and Responsibilities 
A leader needs to clearly define OI roles and responsibilities in their organization 
to ensure the successful adoption and implementation of OI strategies. In this study, five 




implementation of OI pharmaceutical R&D projects. The five participants described the 
roles and responsibilities of many of the staff involved in the process. Participants 
described OI actors as scouts, scientists, business development staff, alliance 
management, integration management, and academic researchers. P1 said: 
We involve all the department stakeholders that are important for the success of 
the project. Projects are selected at different stages of development and each 
project is unique so there is no one size fits all. Aside from the scientists, many 
departments often need to be involved to some degree e.g. patent attorneys, tax 
accountants, etc. 
Each project is unique and may require different capabilities. Therefore, it is 
important to have staff involved in OI projects with defined roles and responsibilities. 
Individual competencies of team members, including knowledge, skills, and attitude are 
of the greatest importance to the success of the OI project. OI strategies require leaders to 
find, identify, select, and evaluate projects that are aligned with overall business 
strategies and then integrate projects seamlessly into the organization. 
All interview participants (P1-P5) stated that to find and identify new OI projects 
aligned with high-level strategies, they implemented search and evaluation teams within 
the R&D organization. Search and evaluation teams are integral to the success of finding 
the right projects. They are scouts for the organization that assist in implementing 
strategies defined by research units. Zynga et al. (2018) said scouts identify advances in 
science and technology that can be useful for the company. Hosseini et al. (2017) said 




of creating successful OI outcomes. Strategies involve either directed searches in a 
specific technological area or via an undirected search for new technological 
opportunities. 
All participants stated search and evaluation teams are external facing the 
organization’s R&D department. The role of the employees in search and evaluation 
teams is looking for specific external partnering collaborations, licenses, or acquisition 
opportunities, typically in the preclinical or discovery space across a span of technologies 
or therapeutic areas. P1 said: “The employees in search evaluation are often former 
researchers; therefore, they understand the needs and the technologies. The staff in search 
and evaluation teams have a specific scientific skill set that helps to serve their purpose” 
P5 stated: 
I start with a clear understanding of our internal strengths and the areas we have 
gaps. If I understand our strengths and weaknesses accurately, then this 
information helps to define the space broadly and provides direction to external 
innovative opportunities.  
P5 said: “The specific areas that I am scouting externally are technologies around large 
molecule discovery and development, and digital platforms.” P2 said: “The search and 
evaluation team is a global group that helps all the research units find projects. After the 
search and evaluation team find the projects, then it is up to the business development 




Search and Evaluation Team Strategy 
Search and evaluation teams in the pharmaceutical industry use several strategies 
to find projects that are aligned with the overall business strategy. Some of the strategies 
scouts use to search and find projects include their personal and professional networks, 
literature searches, academic institutions, patent data, and conferences. Zynga et al. 
(2018) said scouts are very important to developing a robust open innovation program. In 
addition to helping pharmaceutical leaders discover novel technology, scouting 
techniques, data mining, data access systems, and information technology support the 
absorptive capacity of firms (Zoebel & Hagedoorn, 2020). The absorptive capacity of the 
firm is the leader’s ability to recognize the value of new technology and then acquire and 
integrate the asset into operations and apply it in the development of new products.  
When leaders implement OI strategies, they must create additional processes to 
deal with the scale and scope of external inputs. The ability to be able to accommodate 
these additional processes to evaluate new technologies and innovations is a firm’s 
absorptive capacity. An external technology scouting team commonly uses an open 
search method to facilitate finding innovations (Wang & Quan, 2019). Organizational 
leaders must develop processes to select the most valuable ideas and integrate them with 
their existing knowledge base (Rasiah, 2019). Having enough absorptive capacity in a 
firm is critical to successfully implementing open innovation strategies.  
Networks: personal and professional. Networking is an important method that 
scouts use to find new technologies. Scouts and scientists are key individuals in open 




exploiting it (Rasiah, 2019). Scouts help connect individuals, firms, and organizations to 
support innovations openly across innovation systems. Hosseini et al., (2017) discussed 
peer leadership in the OICF. Hosseini et al., (2017) suggest peer leadership helps ensure 
OI progress and success despite the absence of a formal hierarchy. I would argue that 
networking is a form of peer leadership because networking is an informal method to 
connect with others. P5confirmedthe importance of peer leadership commenting: 
Scientific connections are the other place where ideas and projects are discovered. 
The scientists that are in the search and evaluation team and all the PhDs that are 
all within the research unit have connections. This staff has contacts from the 
universities where they received their PhDs. Scientists use these networks to bring 
forward ideas that look promising. 
Furthermore, P5 said: 
Our group is externally facing, those of us who are externally facing through 
going to conferences and staying current with the literature learn who are the key 
collaborators and subject matter experts and leaders in the field, whether they are 
academic, startups, or pharma peers. 
Conferences and meeting attendance. Search and evaluation scouts attend 
conferences and scientific meetings where they can network and find new technologies. 
Conferences such as the annual BIO International Convention play a critical role in the 
pharmaceutical industry leaders’ sources of information and networking. The conferences 
are valuable sources of information, industry trends, and current news and provide 




technologies and opportunities. Professional conferences facilitate the convergence of 
these informal leaders with mutual interests that may increase the occurrences of 
collaborations. 
In addition to numerous networking events, many conferences also facilitate one-
on-one meetings. The one-on-one meetings are organized scheduled interactions called 
partnering meetings.  Partnering meetings are scheduled in advance of the conference so 
the interactions between participants are deliberate. Scheduling the partnering meetings is 
enabled through an online portal provided by the meeting organizers that is accessed on 
the conference’s website. The partnering meetings typically last only 30 minutes. 
Although the duration of the initial meeting is short, the relationship between the parties 
may continue after the initial interaction. P1 said:  
We attend conferences such as JP Morgan and the BIO conferences, those are big 
partnering conferences that offer a lot of networking opportunities. The 
conferences offer one-to-one partnering sessions that we can register for. These 
partnering sessions are an opportunity to meet with company representatives that 
want to pitch their technologies. Each company will meet with the business 
development staff and search and evaluation scouts at these conferences for 30 
minutes. Each company has representatives who provide a brief presentation of 
their technology and value proposition. Some of these presentations are 
unproductive and others lead to professional relationships. If the technology is 
early in development, we may stay in contact with company leaders and check 




technologies that are further in development, if we are interested, we may start a 
smaller research agreement together and then if it is successful, we build upon it. 
Not all conferences have partnering meetings.  
The J. P. Morgan Healthcare Conference referred to by P1, is a premier event for 
conferences and do not have centrally organized partnering sessions. P1 noted with the J. 
P. Morgan Healthcare Conference business development, scouts, and executives arrange 
meetings with the innovators. Nonetheless, conferences are gathering forums for large 
numbers of participants interested in a similar topic. Therefore, there is an increased 
opportunity of meeting other participants who may have an interest in partnering. 
Hosseini et al. (2017) OICF did not specifically address conferences and scientific 
meetings as sources of innovation. However, Hosseini et al. did reference boundary 
spanning and social brokerage as important aspects of OI implementation. Individuals 
with social brokerage capabilities can connect the right actors that would normally not be 
in contact and ensure that external ideas and knowledge are utilized. Conferences enable 
social brokerage between individuals and organizations. 
Another important concept noted in the OICF is boundary spanning, which is the 
ability of individuals to manage heterogeneous information and clearly articulate the 
value proposition. Boundary-spanning enables cognitive distance to be overcome and 
mutual understanding established between partners within and outside organizational 
boundaries (Hosseini et al., 2017). Conferences promote boundary-spanning interactions 
between internal and external the participants. Social brokerage and boundary spanning 




Literature search. Scouts’ other method for identifying projects is by searching 
the scientific literature and consulting with thought leaders. Recent scientific literature 
and thought leaders can provide direction for the scout’s searches. P1said: “In addition to 
the big conferences, scouts and scientists also scour the scientific literature, looking for 
technologies and projects that fit our business strategy. The scouts use the literature as 
leads to find innovations and subject matter experts. In support of the OI business model, 
P1 said: 
Well, there's no way that the organization has all the resources to do everything 
internally. We need to be realistic and understand we cannot be the best at 
everything. There are people out there that are better than us in certain areas and 
maybe ahead of our organization in the development timeline. When these 
circumstances exist, we may go outside the organization.  
Universities/academia. Another source of innovation that scouts use to identify 
new projects is academic sources. P4 suggested search and evaluation scouts visit with 
researchers in academia to identify potential projects that are aligned with our goals and 
therapeutic areas. To participate in the program the researcher must sign an agreement 
that explicates the terms of the partnership. P4 said: 
We intentionally recruited staff from outside the company because we needed 
staff that thinks differently. With the agreement we have with academics there is 
very much an open sharing of information. Just as we run a drug discovery and 
development program we would envision needing to prove or disprove the 




around the knowledge the academic principal investigator brings to the project 
regarding the biology and the drug target. 
P4 also said: 
Our researchers can go in and work in the academic institutions’ labs, and the PIs 
can come in and work in our labs as well. We share the data in real-time, and we 
have joint project team meetings where we problem solve, and we review the 
data. The academic institution becomes an extension of the company to share 
knowledge and improve the chances of producing a product.  
P4 suggested: 
The approach I would call a passive approach is when we put out a call for 
proposals, through our network community, once or twice a year, where we state 
the type of project we are interested in and the stage at which the research needs 
to be at. The interested party would also need to agree to disclose information 
requested by the company related to the project for due diligence. The other 
approach is a more active targeted approach, and this is where our scouting team 
focuses a lot of their activities. The scouts deliberately go out and search for 
academic principal investigators (PI) who they know are working in research 
areas of interest to us. The scouts then build relationships with these PIs and see if 
there is a research project, they can work on together. 
To succeed in OI, organizations must develop capabilities related to knowledge 
exploration, retention, and exploitation. Hosseini et.al. (2017) does not specifically 




the high-level capabilities. Hosseini et.al. Methods capability includes the adoption of 
appropriate tools, techniques, and practices that support knowledge capabilities and 
integration. Establishing collaborations with academia could be considered a strategy. 
Universities scientists produce science-related knowledge that is the output of 
fundamental research in basic sciences. Researchers in universities can potentially 
generate radically new technologies (Colombo et al., 2021). University researchers 
possess state-of-the-art technical knowledge that is generated by applied research 
programs and has a broad range of applications in different technological areas.  
Scientific knowledge in academia is potentially a valuable input to firms’ 
innovation activity but is often generated with little consideration for its direct 
commercial application. Researchers in academia can be thought of as an extension of the 
company’s labs and workforce and therefore, relationships with academia could 
potentially expand the company’s absorptive capacity (Tajudeen et al., 2019). Academic 
researchers’ efforts are often not generated with a commercial product in mind; therefore, 
a pharmaceutical company leader would need a process to harness the researchers' efforts 
directing them toward the intended endpoint of developing a therapeutic for a particular 
disease. The pharmaceutical managers in this single case study use an agreement with the 
university and PI to help direct the research efforts toward the intended therapeutic area. 
The relationship with academia has been successful. P4 stated “After 10 years, 
this collaboration with academia has been fruitful.” P4 stated the open innovation model 
with the universities started as an experiment and has been successful in the 10 years the 




External knowledge exploration refers to methods to develop potential absorptive 
capacity. Because academia is an extension of the company’s labs this agreement with 
academia expands the organizations networks and their available absorptive capacity 
(Burcharth et al., 2017). The complementary nature of internal and external knowledge 
exploration requires an integrative approach when implementing OI. 
Business and OI Strategy Alignment 
The second theme identified was business and OI strategy alignment which is one 
of the components of the OICF strategy alignment. To benefit from OI, organizational 
leaders must align their OI strategy with their business strategy. Organizational leaders 
who are searching for opportunities have different priorities than organizational leaders in 
a defensive mode (Hosseini et al., 2017). Firms searching for opportunities want to 
balance their search breadth, the number of sources and channels used to search for OI 
projects, and the intensity of each effort (Cammarano et al., 2019; Naqshbandi et al., 
2019). Absorptive capacity has been thoroughly researched and therefore R&D leaders 
should be aware of the negative impact when their organization reaches an imbalance of 
search breadth and intensity that results in decreasing productivity. This inverted-U 
relationship between search breadth and intensity is because the absorptive capacity is 
exceeded.  
To prevent the problem of exceeding absorptive capacity from occurring, the 
R&D leaders need to have a clear business strategy. P1 said:  
Our job is to find the science and technology that is considered the best science 




into the organization through a license or to work collaboratively with the partner 
organization.  
The overall strategy needs to be communicated by the leaders. Barham et al. 
(2020) research findings showed that there is a positive correlation between management 
support of OI and the possibility of successful adoption of OI. Moreover, Barham et al. 
results offered insight on some of the dynamics of how management support affects OI 
adoption. P1’s comment suggests that the senior leaders in this organization have 
provided a clear strategy and support for OI to employees. Barham et al. posited 
employees’ perceptions of management support for open innovation will correlate 
positively with firm adoption of open innovation. The provision of resources to support 
the OI strategy can demonstrate the leaders' support.  
To identify projects aligned with the high-level strategy the leaders of the 
organization implemented search and evaluation teams within the R&D organization. The 
search and evaluations team’s role are described in an earlier section, roles, and 
responsibilities. The organizational leaders have demonstrated support of OI through the 
implementation of the search and evaluation scouts. The scouts drive the strategy by 
implementing the action plans provided by the management of each research unit.  
Moreover, each research unit has a triad which is the three leaders that are 
responsible for each research unit, research, development, and commercial. The leaders 
of the research units provide a more detailed strategy for the scouts. The triad explicates 




technologies of interest. The elucidation of the strategy provides a focus for the scouts’ 
searches. P1 stated: 
Business development reports to the Chief Business Officer (CBO) this 
department is separate from the R&D organization. Each Chief Scientific Officer 
(CSO) in the research units creates its strategy. The CSOs of the research units 
create a strategy in conjunction with, the Chief Development Officer and the 
president of the business unit and these three leaders need to be aligned with 
regards to the early-stage assets that will be developed and commercialized within 
the organizations business unit. The organizational structure promotes alignment 
throughout the organization. 
Furthermore, P1 said:  
We must prioritize our portfolio because each research unit only has a finite 
budget to spend on their assets. The leadership of the research units goes through 
an annual prioritization exercise where they look at the budgeted dollars available 
and all the programs and decide which programs they can afford to pursue.  
P1 said:  
Since it is unlikely, we can afford all the programs, sometimes the leaders will 
look to partner one of our assets with someone else. There is no one size fits all 
for R&D projects. It is important to consider risk and reward. The circumstances 





The research and development teams and the commercial teams need to have their 
goals aligned. If the business unit has no interest in the research deal or the 
program is not commercially viable then the business unit will not want to 
allocate a budget to buy the asset from the research unit. This is a deal that should 
not be executed. 
P2 suggested the importance of teamwork: “We need to have a mentality to support open 
innovation working together and collaborating to take advantage of science beyond our 
walls.” 
Hosseini et al. (2017) confirmed the importance of the organization's strategic 
alignment suggesting the high importance of an organization’s strategic alignment 
regarding OI. The strategic alignment in this pharmaceutical organization seems to be 
very important for implementing OI based on the interview data. Hosseini et al. indicated 
that contextual factors strongly impact an organization’s strategic orientation. In this 
single case study, the context is the US pharmaceutical industry where leaders are always 
looking for new opportunities to improve patients’ lives.  
Leadership Attention 
Leadership attention is the third theme identified in this study. Leadership 
attention is one of the components of the OICF high-level strategy culture. Employees’ 
perceptions of management support for OI will correlate positively with firms adoption of 
open innovation (Barham et al., 2020). Hosseini et al. (2017) proposed in the OICF that 
the level of leadership commitment and attention impacts the effectiveness of OI. Senior 




organization must articulate OI goals via written and spoken communication. Hosseini, et 
al. suggested sharing success stories with the employees is one technique that can be used 
to encourage employees to actively search outside of the organization for new ideas and 
technologies.  
By implementing appropriate incentives, senior management can also foster 
employees’ engagement throughout different hierarchy levels in OI activities. Incentive 
structures that foster acquiring innovation from external sources can support moving 
from a NIH to a proudly-found-elsewhere (invented anywhere) attitude (Hosseini et al., 
2017). Senior management providing metrics for OI implementation can also be an 
effective method to engage the employees and encourage their OI participation. 
P5 stated: 
First, I think my role is important and valued at the corporate level. So 
organizationally I am part of a group that has its explicit mandate to essentially 
use open innovation strategies. We are intentionally separate from those core 
science and technology lines, so we do have that independence and autonomy to 
objectively look at assets and technologies outside of the company so 
organizationally that's very supportive in that regard.  
Secondly, P5 said: 
The CEO articulated quantifiable metrics directly geared towards open 
innovation. Specifically, we have quantifiable metrics and goals of projects, 




given year, so that once again organizationally creates a mandate that will be 
assessed on that the whole organization needs to embrace.  
P5 also said:  
On the cultural, softer side, several individuals are well regarded in the company 
and well respected in terms of their scientific and strategic leadership that fully 
embrace and promote open innovation programs, both in terms of supporting 
funding for these projects from their budget, as well as advocating for projects 
that don't necessarily come from inside. 
P5 suggested: “I think that it is a lot harder to quantify culture because it is more of a 
qualitative cultural piece that also supports the open innovation model. It is not uniform 
across the organization, but some individuals drive OI.” P2 stated: 
Yeah, so the Oncology department has always been very open to collaborating 
with outsiders. I think it is a great strategy and culture that this is how we become 
more successful. Using a business model that is including open innovation so that 
we can get access to the best talent and technologies and information to move 
things forward as quickly as possible and be competitive. So, I think, because the 
strategy has always been there, and the leaders are all very supportive. I think the 
leaders of the group certainly sets the tone for open innovation culture, and how 
we do business. 
All the participants comments suggest employees’ perceptions of management support 





The fourth theme identified in the study was OI decision-making which is one of 
the four elements composing the high-level strategy of governance in the OICF. Hosseini 
et al. (2017) suggested OI experts have highlighted the relationship between culture and 
governance among the capabilities related to OI decision-making. Organizations that 
have a risk-averse culture may struggle with the implementation of OI projects. Many 
decisions need to be made for implementing and an OI strategy.  
Also, according to all participants, there is no one size fits all approach, each 
project has unique challenges and needs to be managed. Since the participants suggested 
that there is no standardized approach to implementing a project and each project has 
unique challenges, it would follow that there will likely need to be a greater amount of 
decisions. The heterogeneity of the challenges naturally leads to more decisions that need 
to be made. For an organization to improve OI performance improving decision making 
would be a step in the right direction. 
Empowering employees to make a decision is an important step in improving OI 
performance. Naqshbandi et al. (2019) suggested that an empowering leadership style 
creates an employee involvement climate and empowers employees to involve them in 
relevant decision-making. Empowering employees to make decisions will subsequently 
enhance a firms’ OI performance.  
 Decision-making is a very important aspect for the success of open innovation 
projects. The time parameter in decision-making is critical; an organization that can 




P5 said: “In deciding to implement OI we need to have a good idea of our internal 
capabilities. If the project can be completed internally then the leaders of the organization 
will likely do the project internally.” 
The interview participants’ statements are consistent with Lee et al. (2019) 
findings that suggest if the employees of the firm possess the capabilities then the leaders 
will use closed innovation. If the firm does not have the capabilities, then the leaders will 
use an open innovation strategy. 
P1 said: 
We evaluate our internal team and their capabilities. Is the project something that 
we can do successfully on our own? Does the project need to be supplemented 
with capabilities that we do not have? Will this project take us longer if we do it 
on our own? If another company is 18 months ahead of us in development, we 
may want to partner with them to increase the speed to market. Therefore, we may 
pay for a collaboration with a partner who is further ahead. So, if an organization 
is way ahead, and their science looks as good or better than ours we will likely 
partner with them. 
Lee et al. (2019) also suggested that when the projects have high complexity that 
organizations tend to use OI strategies. Conversely, when the complexity of the project is 
low then the organizations tend to use a closed innovation strategy. 
P1 suggested:  
When we got into gene therapy, there was a lot of early-stage research, but we did 




gene therapy deals, we also had to commit to building a 100 million-dollar facility 
to build up our capabilities to manufacture. Also, we needed to hire staff that had 
the knowledge to manufacture gene therapy products and scale them up for larger 
clinical trials and eventual commercialization. 
P5 stated: 
We need to justify additional expenses and opportunity costs to work and 
collaborate outside of the organization. We need to be able to justify the 
investment in OI. If we do not have very strong alignment, and particularly 
technical champions from within those expert lines then we have little chance of 
getting senior managements’ approval. Also, we need a good internal advocate 
(champion) or our chances of success with the OI project are very low. 
The decision to advance a project needs to have support from senior management. 
When there is a project advocate who can articulate the value proposition of a project 
then the project is likely to move forward. If a project does not have an internal advocate 
(champion) then it will likely not be successful. Having a project advocate that can 
articulate the value proposition of the OI project is essential to the success of OI projects.  
P5 suggested for a project to be successful the project needs a champion (advocate).  
P5 said: 
Scientific thought leaders from within a research unit in the organization need to 
understand and be able to articulate the value proposition. The scientific thought 
leaders need to be able to help communicate the value proposition up through 




In R&D intensive firms, innovation decisions have a strategic nature and are 
critical drivers of a firms’ competitive advantage (Bogers et al., 2018). Therefore, we 
would expect innovation decisions to be more centralized at the top of the corporate 
hierarchy. The pharmaceutical organization in this single case study is aligned with 
Bogers et al. (2018) study findings. The decision making is at the research unit level 
driven by the high-level strategy and portfolio prioritization. 
P5 observed: 
Without a scientific thought leader that can articulate the value proposition that 
there have been several failed attempts, where even some technologies I have 
seen that I thought could be incredibly valuable and disruptive for our industry 
and potential for the organization but they are a bit outside of the realm of our 
traditional capabilities and traditional approaches, and not necessarily filling 
incremental gaps in our capability 
P5 suggested:  
I would say if the gap in skills is too large for a given project this would not be a 
good project to pursue. If it would require significant advances along with a large 
trajectory of technology and capabilities it may be too far to the side of our core 
expertise. If the technology is something so radical to the way we do things today, 
that it is seen as too disruptive we may not want to pursue it.  
P5 suggested that they have tried to advance some projects that were radical 
innovations but were not successful because the supporting technology needed to catch 




and can be very effective at combatting certain cancers. The challenge with implementing 
this technology was the time and cost to personalize the T-cells. This project failed 
internally because of the large gap in capabilities. The leaders of the firm were able to 
acquire a company that had the capabilities to get closer to implementing this paradigm.  
Kim and Park (2013) said firms incorporating technologically distant knowledge 
into their organization are likely to face difficulties in assimilating and utilizing the 
knowledge. The gap in knowledge from other technological contexts that made it 
attractive for high-impact innovation creates problems in integration and assimilation at 
the firm level. Significant effort and expertise on the part of the firm are required to 
assimilate and exploit the knowledge. In this single case study, the leaders of the firm 
found it was more cost-effective to partner with an outside organization that possessed 
CAR-T expertise. Three of the participants (P1, P3, and P5) suggested projects that are 
incremental improvements are less risky and more likely to be pursued if the project 
aligns with the business strategy. P3 stated: “We use OI to improve the product for the 
patient and to make things better for the patient.” 
P5 suggested:  
The scouts can use their knowledge of the organization's technical strength to 
bolster the case and ultimately progress, any kind of an open innovation project. 
Those open innovation ideas that are too far away from our strengths are much 
harder for the organization to take the risk to engage in. If we are too far out of 




projects that would require a lot more resources. I guess the amount of resources 
needed to raise the project would be most of the problem. 
An important aspect of risk management and decision making is to evaluate each 
project thoroughly before investing too much time and resources. P1, P2, and P4 
suggested due diligence for any OI project is important because they have found that 
sometimes the science supporting the innovation is not reproducible, an important 
decision point. P2 said: 
We can understand the science and the mechanism of action, but we still need to 
confirm it is reproducible. We have found some projects are not reproducible 
internally. So, the project looks great on paper, but when you do your due 
diligence you cannot reproduce the results. This will result in not pushing through 
a deal. We have terminated deals because we were not able to reproduce the 
results internally.  
All participants indicated due diligence is an important method to mitigate the financial 
risk of the project. 
Applications to Professional Practice 
I conducted this study to explore the strategies that US pharmaceutical company 
leaders have used to develop and implement OI R&D projects. The themes I discovered 
from the use of five semistructured interviews, were strategies pharmaceutical managers 
should contemplate if they plan to implement an open innovation business model for their 
company. Pharmaceutical managers should be particularly attentive to these four areas 




strategy alignment, leadership attention, and OI decision making. The findings in this 
study have significant applications to professional practice that are relevant to 
implementing OI in the pharmaceutical industry to develop novel therapeutics. 
Of the four themes discovered, OI roles and responsibilities and business and OI 
strategy alignment was revealed more frequently than leadership attention and OI 
decision making. The increased frequency of OI roles and responsibilities and business 
and OI strategy alignment would suggest that these strategies may be more important 
areas to focus efforts. Nonetheless, leadership attention and OI decision making are also 
important factors for implementing OI and are often closely related to OI roles and 
responsibilities and business and OI strategy alignment.  
The applications for professional practice would be to first define roles and 
responsibilities for all key positions related to OI implementation. One role that seems to 
be of significant importance is the search and evaluation function. These employees 
typically have a graduate degree or medical degree and have experience doing biomedical 
research. Formal training and research experience are important training and skills for the 
scouts searching and identifying opportunities aligned with the leaders' business strategy. 
In a pharmaceutical company, these staff can be recruited from within the company 
because many of these organizations have many employees with PhDs and/or MDs. 
Alternatively, leaders can recruit qualified staff from outside the company. 
Also, encouraging staff in the OI positions to network, attend conferences and 
meetings, and keep up to date with the literature will be helpful for all roles. The OI 




employee tries to expand their professional network, the network will be much larger. 
The additive effect of each employee’s network expands the network reach, increasing 
the chances of finding novel innovations. 
 Staying up to date with literature is imperative for all employees involved in the 
OI process. The scientific literature was found to be a good place to find leads, subject 
matter experts, and thought leaders in areas of interest. Pharmaceutical leaders should 
lower the barriers to obtaining access to the literature with subscriptions to multiple 
journals. Pharmaceutical leaders will benefit from implementing or improving upon these 
strategies, which may have a largely positive effect on improving the odds of finding 
novel innovations that can help maintain or achieve a competitive position in the 
pharmaceutical industry.  
Implications for Social Change 
The results of this study will have direct implications for social change by helping 
improve pharmaceutical leaders' efficiency in discovering and developing novel 
therapeutics. OI activities result in a diverse network of collaborations with partners that 
positively influence a company’s innovation success (Rauter et al., 2018). Pharmaceutical 
leaders implementing the findings from this study may increase the efficiency of 
discovering and developing novel therapeutics. An increase in the efficiency of 
discovering and developing novel therapeutics may lead to cost-effective therapeutic 
medicines that provide a better quality of life for many patients and in some cases may 
save lives (Hunter et al., 2018). Pharmaceutical leaders implementing OI strategies will 




of discovering and developing novel therapeutics more efficiently could lead to a 
decrease in R&D costs with a resultant decreased cost of novel medicines. 
Recommendations for Action 
The findings from this study may be beneficial for pharmaceutical leaders 
intending to implement OI strategies to discover and develop novel therapeutics. Based 
on the findings of this study, defining the employees' roles and responsibilities, and 
aligning their actions to implement the strategy should lead to success in implementing 
OI. 
Recommendation 1 
Leaders need to create a clear strategy for the employees to advance their mission. 
The participants (P1-P5) consistently acknowledged that the OI strategy was set forth by 
the managements’ innovation strategy. de Oliveira et al. (2018) suggested the leaders' 
strategy should clearly define the innovation-related strategic positioning. A defined 
strategy is a critical success factor for implementing OI strategies (de Oliveira et al., 
2018). The leaders need to decide if they are going to search for radical innovations, 
incrementally improve existing technology, or a combination. To be successful the 
leaders will need to ensure they have enough absorptive capacity and that absorptive 
capacity is managed throughout the innovation process. Managing knowledge and 
technological competencies will improve a leader's chances of success.  
Recommendation 2 
After defining the business strategy, I would recommend defining the roles and 




involved in the OI process. One of the positions that participants indicated was key is the 
search and evaluation function. The leaders of the team need to have a focused approach 
to best utilize finite resources. Having a team skilled in identifying innovations that fit the 
overall business strategy is a critical factor. All participants were well aware of 
absorptive capacity and understood they were not able to accomplish everything.  
The search and evaluation staff help to moderate the absorptive capacity. The 
participants suggested that the company develops absorptive capacity through routines 
and processes, especially information search practices, market monitoring procedures, 
and risk management. Senior management prioritization and portfolio optimization were 
often cited as drivers of their OI search strategy. I would recommend prioritizing the 
goals and then using OI to explore and exploit those areas that will bolster and advance 
the business strategy. 
Recommendation 3 
The third recommendation would be to explicate an OI strategy that would 
achieve the business goals. Creating an OI strategy would provide direction for the staff 
involved in the OI processes to ensure that resources are being used efficiently. Having 
an OI strategy will be imperative to managing absorptive capacity. The P1-P5 suggested 
that they consider the feasibility of doing a project internally before committing to 
establishing external collaborations. Furthermore, senior management's explication of the 
OI strategy will help to reduce the chances of not-invented-here syndrome (NIH). Senior 





My fourth recommendation is to assemble an alliance management team that is 
skilled at managing employee relationships in collaborating organizations. Managers 
should develop high internal capabilities to integrate external knowledge and enhance 
potential absorptive capacity for future knowledge transfer and knowledge sharing 
(Martinez et al., 2017). Once innovations are discovered and secured, assimilating those 
innovations into the organization is important for the success of the project and to ensure 
it is productive. One participant, P3 was directly involved with managing external 
alliances and suggested alliance management is a critical function for OI projects to be 
productive. P3 suggested keeping the staff focused on the patients waiting for the 
medicines helps to reduce resistance between the organization's teams and focus their 
efforts. After investing the time and resources into securing a collaboration, P3 suggested 
managers of both organizations want to ensure the project is productive. One of the 
reasons OI projects fail is because of the lack of project assimilation into the organization 
resulting from uncertainty on the benefits of an alliance, a lack of information on 
potential partners, and concern over sharing information with potential competitors 
(Hewitt-Dundas et al., 2018). 
Recommendations for Further Research 
One of the limitations of this study is that it was a single case study in a large US 
pharmaceutical company. To improve on this limitation researchers could use a multiple 
case study for future research to explore strategies US pharmaceutical leaders use to 




case study did not use crowdsourcing as one of its strategies. Crowdsourcing is a strategy 
used by some pharmaceutical companies; therefore it would be a good reason for a 
multiple case study because there may also be other differences between companies. 
Furthermore, a researcher could also use the open innovation capability framework as a 
lens to research implementation strategies in small and medium-sized companies that 
have fewer resources.  
Another limitation of my research was the participant sample size. Interviews 
with five pharmaceutical R&D directors is a relatively small sample. The final limitation 
of my study was the use of semistructured interviews as my primary data collection 
method. Semistructured interview participants may not be equally articulate and 
perceptive and thus may lead to less robust data. 
Reflections 
I started the doctoral journey to achieve the height of my education career and 
give back to my chosen industry, the pharmaceutical industry. I chose to use a qualitative 
approach because to me it was a new methodology, it was something new to expand my 
knowledge. Having worked in biomedical research for over 36 years I was comfortable 
with quantitative approaches. I was informed at the beginning of my doctoral journey as I 
considered topics that most qualitative researchers are extroverts and quantitative 
researchers tend to be introverts. Using a qualitative approach would be a stretch for me 
since I am more introverted.  
 I found the qualitative approach to be more challenging but rewarding. As the 




did not creep into my decisions on data collection and analysis. Throughout the research, 
I needed to reflect on my experience to guard against my personal biases that might have 
an impact on my decisions. Furthermore, the research was performed at my employer and 
therefore I needed to be more vigilant in guarding against my biases and protecting the 
participants.  
Conclusion 
The purpose of this qualitative single case study was to explore strategies US 
pharmaceutical company leaders used for successfully developing and implementing OI 
R&D projects. I conducted semistructured interviews via synchronous computer-
mediated interviews to explore the implementation experiences of five directors of R&D. 
I used the OICF as a lens to explore the implementation of OI strategies and discovered 
four themes. The four themes discovered associated with successfully developing and 
implementing OI R&D projects were: (a) roles and responsibilities, (b) business and OI 
strategy alignment, (c) leadership attention, and (d) OI decision-making. I triangulated 
these themes with public websites of the organization in the single case study and 
available literature and found the information discovered was in alignment with these 
themes.  
Pharmaceutical R&D directors may benefit from this study by modifying their 
implementation strategies for OI projects. The modification of their strategy may lead to 
greater success in the efficient implementation of OI projects and a reduction in R&D 
costs. Pharmaceutical leaders implementing these strategies may have a beneficial impact 
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Appendix B: Recruitment Letter 
Doctoral Student seeks participants for an Interview study 
 
The research Explores strategies US pharmaceutical company managers use for 
developing and implementing open innovation pharmaceutical R&D projects. The 
researcher is inviting participants who possess the knowledge to contribute relevant 
information to the research. This interview is part of the doctoral study for John A. Maher 
D.B.A. student at Walden University. Interviews will take place during the weeks of 
XX/XX/XXXX to XX/XX/XXXX. 
About the study: 
• One 40-60-minute interview via WebEx, Skype, or Zoom that will be audio 
recorded. 
• After the interview you will review a summary of the interview transcript for 
accuracy (~15-20 minutes) and follow up questions if applicable (5-10 minutes). 
• You would receive a $25 Amazon gift card as a thank you. 
• To protect your privacy, you will be assigned a pseudonym. 
Volunteers must meet these requirements: 
• Possess knowledge and experience with open innovation projects. 
• Director level 
 
To confidentially learn more about the study or request a consent form please 
contact the researcher: 
 





Appendix C: Consent Form 
You are invited to take part in a research study that explores strategies US 
pharmaceutical company managers use for developing and implementing open 
innovation pharmaceutical R&D projects. The researcher is inviting participants who 
possess the knowledge to contribute relevant information regarding strategies for 
developing and implementing Open Innovation R&D projects to participate in the study. 
I obtained your name/contact info via the guide. This form is part of a process called 
“informed consent” to allow you to understand this study before deciding whether to take 
part. This study is being conducted by a researcher named John A. Maher, who is a 
doctoral student at Walden University.  
Background Information: 
 The purpose of this study is to explore strategies US pharmaceutical company 
leaders used for developing and implementing Open Innovation R&D projects. The 
participants will comprise US pharmaceutical R&D directors in one pharmaceutical firm 
that has successfully used Open Innovation strategies to develop and implement R&D 
drug development projects. 
Procedures: 
 
 If you agree to be in this study, you will be asked to:  
• Answer 10 interview questions via Webex or Skype (30 -60 minutes). 
• The interview will be recorded and kept confidential. 
• The time for the interview will be at your convenience. 




• Answer follow up questions if applicable. 
 
 Here are some sample questions:  
 
1. What strategies did you use to implement an open innovation (OI) R&D 
projects? 
2. How did you identify new R&D projects to pursue using an OI strategy? 
3. How did you decide which OI strategy to use for an OI R&D project? 
4. What organizational issues did you consider when pursuing a given OI 
R&D project? 
5. What organizational capabilities did you consider when pursuing a given 
OI R&D project? 
Voluntary Nature of the Study: 
 
 This study is voluntary. You are free to accept or turn down the invitation. No one 
will treat you differently if you decide not to participate in the study. If you decide to 
participate in the study now, you can still change your mind later. You may stop at any 
time.  
Risks and Benefits of Being in the Study: 
 
 Participating in this type of study involves minimal risk and minor discomforts 
that can be encountered in daily life such as being asked about your experience with OI 
R&D projects. I anticipate that being in this study would not pose risk to your safety or 
wellbeing.  
  My study findings could be significant for leaders in pharmaceutical firms 




Pharmaceutical leaders intending to implement an OI business model might be able to 
use the implementation strategies that may be discovered through my research. 
Pharmaceutical leaders may possibly use the prospective framework to lead a more 
efficient and effective drug development process for reducing the cost of developing 
drugs and increasing the resultant pharmaceuticals ‘efficacy 
Payment: 
 For your participation in the interviews process and follow-up questions for this 
study a $25 Amazon gift certificate will be provided after the completion of the study.  
Privacy: 
 Reports coming out of this study will not share the identities of individual 
participants. Details that might identify participants, such as the location of the study, 
also will not be shared. The researcher will not use your personal information for any 
purpose outside of this research project. Data will be kept secure by use a code for each 
participant so their identity will be revealed. Furthermore, all files will be password 
protected. Data will be kept for a period of at least 5 years, as required by the university 
and then destroyed.  
Contacts and Questions: 
 You may ask any questions you have now. Or if you have questions later, you 
may contact the researcher via john.maher@waldenu.edu or 845-548-4074. If you want 
to talk privately about your rights as a participant, you can call the Research Participant 




this study is 09-14-20-0674379 and it expires on September 13, 2021. Please print or 
save this consent form for your records.  
Obtaining Your Consent 
        If you feel you understand the study well enough to decide, please indicate your 





Appendix D: Interview Protocol/Questions 
Primary Research Topic 
Development and Implementation Strategies for Open Innovation Pharmaceutical R&D 
Projects 
The Overarching Research Question 
What are the strategies that US pharmaceutical company leaders use to develop and 
implement OI R&D projects? 
Primary Research Goals of the Interview 
The purpose of this interview is to explore the organizational factors and 
capabilities that are critical to employing open innovation strategies for research and 
development projects. The two most important questions in the exploration are 1.) How is 
the decision to use an open innovation strategy for a single R&D project reached? 2.) 
How is the decision to employ any particular strategy reached?  
Initial Probe Questions 
1) What is your title? 
2) What is your role in the organization? 
3) In your own words, what is open innovation? 
Targeted Interview Questions 
1) What strategies did you use to implement an OI business model for R&D 
projects? 




3) How did you decide which OI strategy to use for an OI R&D project? 
4) What organizational issues did you consider when pursuing a given OI 
R&D project? 
5) What organizational capabilities did you consider when pursuing a given 
OI R&D project? 
6) How did you decide which capabilities are important to implement an OI 
R&D project? 
7) How did you decide which employees should participate in the 
implementation of OI R&D projects? 
8) If your organizational culture supports OI R&D, describe how your 
culture supports the implementation of OI R&D projects?  
9)  [If the organizational culture supports OI] Describe the strategies used to 
align the organizational structure to support OI R&D projects? 
10)  What else can you tell me you did to enhance OI strategies? 
Targeted Follow-Up Questions 
 
If time allows targeted questions will be follow up Why questions to discover 
underlying reason for a decision if not already clear.  
Targeted Wrap-Up Questions 
 
If time allows targeted questions will be follow up Why questions to discover 







I will thank the interviewee(s) for his or her valuable contribution and promptly record 
my reflections of each interview process. I will also explain the follow up member 
checking process. 
 
